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ABSTRACT 
Diphenylphosphinyl chloride (DppCl) was used as a coupling reagent in the 
synthesis of Met 5-enkephalin by a modified phosphinic-carboxylic mixed 
anhydride procedure. The use of DppCl and 1-oxo-1-chlorophospholane 
(CptCl) in peptide synthesis was further evaluated by the synthesis of 
analogues of Substance P. It has been shown that these reagents are 
compatible with the unmasked side-chains of methionine and tyrosine during 
the conditions of coupling and deprotection. An attempt was made to design 
substrates which might interact with the Substance P C-terminal amidating 
enzyme. None of the analogues exhibited any significant biological activity. 
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CHAPTER 1 
INTRODUCTION 
1.1. Processing of Peptide Hormones 
From early studies on the isolation and characterisation of peptide 
hormones it became evident that they coexisted with larger polypeptides both 
in the glands of origin and in the circulation systems'. Some of these 
polypeptides were shown to be precursors of the corresponding hormones and 
have been isolated and fully characterised. They have been found to have a 
much higher molecular weight. Sequencing of the precursors has shown them 
to contain several peptide hormone sequences, flanked on either side by a pair 
of basic amino acid residues , usually arginine or lysine (Fig.1.1). It is thought 
that the processing of the hormone is started by proteolytic cleavage with a 
trypsin-like enzyme, followed by removal of the C-terminal basic residues with 
an enzyme with specificity similar to carboxypeptidase B. 
One of the first precursors to be identified was proinsulin (1), and it's 
conversion to insulin (2) has been carefully studied.2 Incubation of proinsulin 
with trypsin produces insulin with two additional arginyl residues on one of the 
C-termini. Prolonged incubation gives rise to cleavage of Arg-Arg bond as 
well as Lys-Ala bond in positions 29-30 of the B chain. So, although trypsin 
cleaves some of the bonds required for the formation of insulin, it does not 
give rise to the correct products. Isolation and sequencing of the C chain from 
pancreases of several mammalian species shows that the major product is 
devoid of the basic C-terminal amino acids originally present in proinsulin. 
Hence a second protease, with carboxypeptidase B like specificity, is present or 
the processing enzyme must be a novel proteolytic enzyme having 
unprecedented specificity which allows it to cleave at neutral as well as basic 
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Processing of Peptide Hormones 
sites in proinsulin. Mixtures of trypsin and carboxypeptidase B have been 
incubated with proinsulin and major products isolated were insulin and the 
C-peptide fragment (3). These in vitro model studies strongly suggest that the 
in vivo converting system may work in a similar fashion. The overall conversion 
is shown below(Fig.2.2). 
In various other systems precursors of hormones have been isolated and 
characterised and found to have the peptide hormone sequence connected to 
the remainder of the peptide chain by a pair of basic amino acids. The 
prohormone of the parathyroid hormone (4) has been identified and 
characterised 	and found to be the same as a larger active peptide called 
"Calcemic Fraction A" earlier isolated by Hamilton and coworkers . The 
precursor is made up of the 86 residue parathyriod hormone with additional 
peptide material linked to its N-terminus via a basic residue. Another example 
is the 90 residue sheep pituitary peptide -lipotropin (5) which contains the 
amino acid sequence of sheep -melanocyte-stimulating hormone (6) (MSH) 
residues 41-58, linked to the remainder of the polypeptide chain at either end 
through a pair of basic amino acids. 
1.2. C-Terminal Amide Formation 
A C-terminal amide functionality has been found in a range of peptides 
varying in size from the three residue thyrotropin-releasing hormone (7) to the 
39-residue growth hormone-releasing hormone (8), and within this range 
>50% of the known peptide hormones are amidated. The amide functionality is 
often essential for biological activity since analogues possessing a C-terminal 
carboxyl group show greatly reduced activity. Also the amide functionality can 
protect, to a certain degree, the peptide from degradation by 
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C-Terminal Amide Formation 
for example oxytocin (9), vasopressin (10) and luliberin (11) have a glycinamide, 
calcitonin (12) and thyroliberin (13) have a prolinamide, secretin (14) and 
ct-melanotropin (15) end in valinamide and gastrin (16) terminates in 
phenylalanine amide, those whose precursors are known all have a glycine 
residue following the peptide fragment (for example the precursors of 
ct-melanotropin,5 and the putative precursors of vasopressin6 and calcitonin7'8). 
Since many of these peptides have little or nothing in common other than 
possessing a C-terminal amide functionality and a glycine residue in the same 
relative position in their precursors it was thought that the glycine was 
involved as a signal to processing amidating enzyme. 
Bradbury and Smyth have managed to isolate and partially purify an 
amidating enzyme from the porcine pituitary9. Ammonium sulphate precipitated 
extracts from porcine homogenates were subjected to gel filtration. A broad 
fraction with amidating activity was collected, which suggested a mixture of 
enzymes with different molecular weights or aggregates of a single enzyme. 
Attempts at further purification using ion-exchange chromatography failed due 
to the instability of the enzyme. Recovery of amidating activity varied from 
10-50% and this was thought to be because of the removal of cofactors, which 
would lead to denaturisation of the enzyme. Thus , for amidation experiments, 
the enzyme was only partially purified, by gel filtration, and was known to 
contain other enzymes such as peptidases. 
Treatment of the model tripeptide DTyrValGly (17) with porcine 
homogenates or chromatographed preparations of the amidating enzyme gave 
the corresponding dipeptide amide DTyrVaINH2 (18). The VaIGly sequence was 
chosen because this was the minimum structural element of corticotropin (19) 
necessary for the formation of the valine amide group present at the 
3 
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C-terminus of a-melanotropin. Due to the presence of aminopeptidases in the 
tissue homogenates the D isomer of tyrosine was chosen for the amino 
terminal residue to prevent degradation. Also the tyrosine could be 
radio-iodinated which was necessary for the assay. The reaction was monitored 
by subjecting aliquots of the reaction mixture to Sephadex SP ion exchange 
chromatography and measuring the radioactivity of the tripeptide and dipeptide 
amide fractions. The overall reaction was found to proceed in a maximum yield 
of 38% in 17hrs. Longer times led to lower yields which suggests that the 
dipeptide amide is being destroyed by other enzymes present in the pituitary 
extract. 
A mechanism was proposed from the results obtained from subjecting 
isotopically labelled tripeptides to the amidating enzyme and analysis of the 
mass spectra of the purified derivatised products. Hence oTyrVaiGly was made 
with both 14N and 15N incorporated into the valyl glycine peptide bond and the 
corresponding oTyrValNH2 was isolated as before. The low resolution mass 
spectra of the trifluoroacetyl derivatives  of the dipeptides gave three ions 
which showed an increment of one mass unit expected from the incorporation 
of 15N isotope. These mass spectra were identical to low resolution mass 
spectra of synthetic dipeptide amides, molecular ion 549 and 550 atomic mass 
units (amu), base peak 346 and 347 amu. High resolution mass measurements 
of molecular ions confirmed the empirical formulae of the isolated compounds. 
From these results the suggestion that the amide group might be derived from 
ammonia either by direct amidation of the valine carboxyl group 
10  or by 
transamidation of the valyl glycine peptide bond11  can now be ruled out. The 
data supports the mechanism that involves the removal of hydrogen from the 
C-terminal glycine or it's replacement by a hydroxyl group followed by 
cleavage of the C-N link (Fig.1.3). A further experiment to support this 
4 
Table I 
Effect of Some Enzyme Inhibitors on the Amidating Enzyme from 
Porcine Pituitary 
Reagent 	 Concentration 	Effect 
Mercaptoethanol I 	mill 
10 mM 	 30% Inhibition 
Jodoacetamjde 1 mM - 
PMSF 0.1 mM 	 - 
Trypsin inhibitor 5 pUg/mI - 
I3enzcthonju111 chloride 0. 1 mA'! 	 - 
Bacitracin 0.1 mg/m1 - 
Pepstatin 5 p-/m1 	 - 
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mechanism involved the use of DTyrValGly made with 14C-glycine. The isotope 
was found to be incorporated into the glyoxylate byproduct. Also the amidation 
reaction was totally unaffected when carried out in the presence of 1mM 
ammonium ion, glutamine or asparagine. 
Studies into the properties of the amidating enzyme showed that its 
activity was not enhanced by the addition of cofactors which have been known 
to be associated with oxidative enzymes (such as NAD,NADH,NADP,NADPH). 
However, when the enzyme was dialysed against ethylenediaminetetraacetic 
acid all activity was lost indicating the possibility that the enzyme is associated 
with a metal ion. Copper II ions were found to restore full enzymic activity and 
cofactors such as ascorbate or catecholamine enhanced this activity. This was 
interesting since hydroxylase enzymes, which also contain copper II ions , use 
catecholamines and ascorbate as cofactors. No decrease in amidating activity 
was observed when specific enzyme inhibitors were used in order to gain 
information on which functional groups were important for amidating activity 
and it was found that there are no sulphydryl, disulphide or serine residues 
near the active site (Table 1.1). All these inhibitors have a potent effect on 
enzymes such as trypsin, chymotrypsin and pepsin, which are similar in nature 
to the proteolytic enzymes, and so could be included in the early stages of the 
purification of the amidating enzyme reducing the proteolytic degradation of it 
by the contaminating enzymes. Finally the presence of oxygen as opposed to 
air, has been shown to increase the rate of amidation three-fold. Although the 
mechanism is not known it is not surprising that molecular oxygen is involved, 
with copper II ions as cofactors, to produce the glyoxylate. 
When studying the specificity of the pituitary enzyme several interesting 
facts arose. Glycine was found essential as the C-terminal residue for 
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amidation to occur9. Substitution of leucine, alanine, sarcosine, lysine or 
glutamic acid did not give any detectable dipeptide amides. Hence the Tyr-Val 
linkage of DTyrVaICOOH (20) would not be expected to break to form the 
DTyrNH2 (21) and DTyrVaICOOH (20) can be ruled out as an intermediate in the 
formation of oTyrValNH2 (18). Substitution in position 2 of the tripeptide with 
phenylalanine or glycine gave, upon treatment with the amidating enzyme, the 
corresponding dipeptide amide at a similar rate to that of DTyrVaIGly13. 
Therefore the pituitary enzyme could be capable of catalysing the formation of 
gastrin, oxytocin and vasopressin as well as hormones terminating in valine 
amides such as a-melanotropin . When position 2 was substituted with an 
acidic residue, for example glutamic acid, or a basic residue, such as lysine, the 
rate of conversion to the amide was significantly reduced. The optimum pH of 
the reaction mixture was found to be 6.7. If histidine is used in position 2 the 
reaction proceeds best at pH7, although not as quickly as with the neutral 
peptides. These results suggest the pituitary enzyme prefers a neutral 
substrate. To further study the specificity, tripeptide analogues of DTyrPheGly 
(22) with neutral D-amino acids in the C-terminal position were subjected to 
the pituitary enzyme14. Initial competition experiments showed that peptides 
ending in DSer or DLeu did not affect the rate of formation of 1251 oTyrPheNH2 
from 1251  DTyrPheGIy. However, addition of DTyrPheGIy (23) or DTyrPheDAla (24) 
significantly reduced the rate of formation of 1251  DTyrPheNH2. DTyrPheGly was 
found to have a larger effect than DTyrPheDAla. Treatment of the pituitary 
enzyme with the four radio-iodinated labelled tripeptides mentioned above 
revealed as expected the analogues ending in DSer or DLeu did not undergo 
amidation whereas the analogues terminating in oAla or Gly gave high yields of 
1251 DTyrPheNH2. It was notable that the amidation of 1251  oTyrPheGly was at a 
much higher rate than 125i  DTyrPheoAla. Thus from these results a peptide 
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terminating in oAIa can be used as a substrate for the amidating enzyme, 
although a peptide ending in LAla cannot. The orientation of the substituent on 
the ct carbon of the terminal residue is therefore important for 
enzyme-substrate interaction. The size of this substituent cannot be too big as 
in the peptides ending in D-Leucine or D-Serine where steric hindrance 
presumably prevents binding. For the amidation of peptides with a C-terminal 
glycine it would seem only one of the ct-carbon hydrogen bonds is broken in 
the initial hydrogenolysis step. The enzyme-peptide interaction can also be 
affected by the penultimate residue where peptides with charged residues in 
position 2 are very poor substrates whereas neutral peptides are very good 
substrates. Interestingly no C-terminal amide peptide discovered to date has a 
charged residue in the C-terminal position. The pituitary enzyme must 
recognise the ct-carbon-hydrogen bond, maybe the ct-carbon-nitrogen bond of 
glycine or o-alanine and the nature of the penultimate residue which would 
suggest the enzyme has a highly compact substrate binding site 
So far all experiments have been carried out using an enzyme extract from 
the porcine or bovine pituitary. It has been shown that this enzyme can 
catalyse the amidation of substrates based on the C-terminal sequence of 
ct-melanotropin and gastrin. Independently an enzyme extract from the bovine 
pituitary has been shown to convert pGlu-His-Pro-Gly (24) to 
pGlu-His-Pro-NH2 (25) (thyrotropin releasing factor)15. A preparation on the rat 
thyroid, similar to that carried out for the extraction of the pituitary enzyme, 
yielded an amidating enzyme with similar properties to the pituitary enzyme. 
Conversion of oTyr-Val-Gly (17), oTyr-Phe-GIy (22) and oTyr-Pro-Gly (26) to 
the corresponding dipeptide amides by the porcine pituitary enzyme occured at 
different rates with DTyr-Phe-Gly being the quickest and oTyr-Pro-Gly the 
slowest. Treatment of the thyroid extract with these three tripeptides yielded 
7 
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the corresponding dipeptide amides at the same relative rates. This is very 
interesting since if the amidating enzyme in the thyroid gland was specific for 
the thyroid hormone, calcitonin, which terminates in proline amide, the thyroid 
enzyme might be expected to catalyse the amidation of DTyr-Pro-GIy faster 
than DTyr-Val-Gly since the latter is a model substrate for the pituitary peptide, 
c-melanotropin. Similarly the pituitary enzyme would be expected to catalyse 
the amidation of valine or glycine containing substrates, reflecting the 
C-terminal sequence of cMSH or oxytocin and vasopressin, faster than 
olyr-Pro-Gly. However, the amidation of the substrates oTyr-Pro--Gly, 
DTyr-Val-Gly and DTyr-Phe-Gly by the amidating enzyme exhibit relative 
reaction rates that are unrelated to the tissue of origin. 
Since the small peptide oTyr-Val-Gly could be amidated it was interesting 
to note the minimum length required for amidation by the enzyme. Using 
competition experiments, very similar to those previously described, 
glycylglycine did not slow oTyr-VaINH2  formation whereas acetylglycylglycine 
did. The interpretation of this was that the amidating enzyme did not accept 
NH3 groups of the glycyiglycine in position 2. This has been seen before when 
analogues with charged residues in position 2 are not amidated by the enzyme. 
Glycylglycylglycine, which lacks the NHgroup in position 2, competed with 
DTyr-Val-Gly for amidation. In general the amidating enzyme only recognises 
two amino acids in the C-terminal region (neutral amino acids in position 2 and 
the glycine) which suggests the enzyme can amidate a variety of peptide 
hormones of varying size, such as the two mentioned previously. The problem 
with repeating in vivo amidations on large polypeptides in vitro is that the 
enzyme extract contains peptidases which compete with the amidation. 
Gastrinylglycine has been converted to gastrinamide using the amidating 
enzyme , purified by gel filtration but without the addition of cofactors, in a 
M. 
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30% yield. Purification and isolation of the amidating enzyme together with the 


















Peptide F (34) 
SerProThrLeuGlnAspClufli. sLysGluLeuclnLysArgTyrGlyClyPheMetArgArgval 
GlyArgProGluTrpTrpMetAspTyrGlnLySArgTyrGlYGlYPheLeU. 
Peptide 1 (35) 
PyrGlyGlyPheMetArgArgValGlyArgProGluTrpTrpMetASpTyrGlflLYSArgTYrGlY 
GlyPheLeu. 
Peptide E (36) 
TyrGlyGlyPheMetArgArgValGltArgProGluTrpTrpMetASpTyrGlflLYSArgTYrGlY. 
BAM22P (37) 




The enkephalins are two closely related pentapeptides which differ only in 
their C-terminal residue. They were first detected as an unknown factor which 
acted as an endogeneous agonist of opiates in the human brain 16,17 and soon 
characterised as low molecular weight peptides18. Mass spectra of the 
acetylated and methylated derivatives were originally used to sequence the 
peptides and showed them to be Leu5-enkephalin (28) and Met 5-enkephalin 
(29)19.  The sequences were confirmed by the isolation and characterisation of 
(28) and (29) from calf brain 20. As a result of discovering the enkephalins, and 
the fact that opioid receptors were known in the CNS, interest soon grew in 
the search for other opioid peptides. These compounds were thought to exist 
since it seemed highly unlikely that animals would have opiate receptors unless 
they already had an endogenous opiate system that interacted with opiate 
receptors in the absence of drugs. 
Also the Met 5-enkephalin sequence was found present in the 9lamino acid 
pituitary polypeptide 	-lipotropin (3O)19.2122,  which has no significant opioid 
activity, and similar pituitary peptides with morphinomimetic activity listed as 
c,y and 5-endorphins(Fig.2.1). These latter peptides have primary structures 
corresponding to sub-units of -lipotropin and as a result -lipotropin was 
thought to be a precursor of Met5-enkephalin22. 
2.2. Biosynthesis 
It was originally thought that enkephalins, as with many other hormones 
and peptides, were derived from a larger precursor which is cleaved and 
degraded at the appropiate positions to give the product. If this is so 
11 
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-lipotropin and the endorphins are highly unlikely candidates as precursors. 
Apart from not explaining the biosynthesis of Leu5-enkephalin, the Thr-Ser 
sequence which links Met 5-enkephalin to the rest of -endorphin would be a 
very unusual cleavage site for enzymic production of the pentapeptide. Also, 
-endorphin and the enkephalins have not been found in the same areas within 
the body. The enkephalins have been found in the posterior lobe of the 
pituitary whereas -endorphins has been found only in the anterior and 
intermediate lobes of the pituitary23, and tissues such as the striatum and 
adrenal medulla have been found to contain only the enkephalins in large 
concentrations but no -endorphin 24'25. However, for conclusive evidence that 
-endorphin is not involved in the biosynthetic pathway of enkephalins it 
would be necessary to isolate a precursor containing the enkephalins' 
sequences. Early work concentrated on searching for the precursor in the 
adrenal medullary chromaffin granules, which were known to contain large 
amounts of enkephalins and no -endorphin25. There are known to exist, within 
the bovine adrenal medulla, a number of polypeptides that bind to opiate 
receptors . The largest protein (>50,000 daltons) when treated with trypsin and 
carboxypeptidase B yields Met 5-enkephalin and Leu5-enkephalin, in a ratio of 
7:126.  Other smaller polypeptides with molecular weights ranging from 
500-22,000 daltons exist, from which Peptide F (34) and Peptide I (35) have 
been purified and their amino acid sequences determined27. Peptide E (36) and 
BAM22P (37) are two smaller peptides which have since been isolated, purified 
and their amino acid sequences determined28. Both of these latter peptides are 
partial sequences of peptide I (Peptide E is fragment(15-39) of Peptide I and 
BAM22P is fragment(1-22) of Peptide E). All these fragments together with the 
larger protein were all thought to be intermediates in the biosynthetic pathway 
of enkephalin. The production of enkephalins is thought to be similar to that of 
12 
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other hormones since the enkephalin sequence within these peptides are 
flanked by two basic amino acids, thought to be signal sequences for the 
processing enzymes. This was originally challenged by the discovery of small 
enkephalin-size peptides two of which were Met 5-enkephalin-Arg-Phe (38)29 
and 	Met 5-enkephalin-  Arg-Gly-Leu (39)30. However, around about the same 
time, larger polypeptides were isolated and sequenced. In one of them, a 3,600 
dalton peptide (40), at the C-terminal end was found Met 5-enkephalin preceded 
by -Lys-Arg- and followed by -Arg-PheCOOH31. In the presence of the 
enkephalin processing enzyme the Met 5-enkephalin-Arg-Phe sequence would 
be expected to be released which would explain its presence in chromaffin 
granules. Similarly a larger peptide (5,300 daltons) (41) was found to contain at 
its 	carboxyl 	terminus 	a 	-Lys-Arg- 	sequence 	followed 	by 
Met -enkephalin-Arg-Gly-LeuCOOH32 which upon treatment with the 
processing 	enzyme 	would 	be 	expected 	to 	give 
Met 5-enkephalin-Arg-Gly-LeuCOOH. With all this known it was interesting to 
note that a precursor (42) had been isolated from the bovine adrenal medulla 
using molecular cloning techniques and DNA sequencing to establish its amino 
acid sequence 33. The proenkephalin was found to contain six Met 5-enkephalin 
and one Leu5-enkephalin sequences. Three of the Met 5-enkephalin sequences 
were flanked with two basic amino acid sequences and two were preceded by 
a pair of basic amino acids and followed by Arg-Gly-Leu-Lys-Arg or Arg-
PheCOOH. The size of the precursor was only 27,300 daltons and was believed 
to be a large fragment of the 50,000 dalton precursor originally observed. Since 
then proenkephalin originating from the adrenal medulla of human 
34  and rat 35 
has also been sequenced and found to be very similar differing only by one or 
two 	amino acids but all containing six Met 5-enkephalin sequences (including 
the two extended enkephalins) and one Leu-enkephalin sequence. 
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Extended Leu5-enkephalins have also been found within the hypothalamus, 
in the brain and in the pituitary. The first was called a-neo-endorphin(43)36 and 
since then several others have been isolated, purified and their amino acid 
sequence determined 37(Fig.2.2). 
Originally it was not fully understood how these extended Leu5-enkephalins 
were involved in the enkephalin biosynthesis until it was reported that the 
amino acid sequence of a precursor to -neo-endorphin (45) and dynorphin 
(47) had been found 38.This precursor was derived from the porcine 
hypothalamus and found to contain the sequences of the above peptides plus 
Leu5-enkephalin itself. This prodynorphin precursor is also known as 
proenkephalin B whereas the proenkephalin is called proenkephalin A. These are 
obtained from different parts of the body and might not be connected. Studies 
are presently being undertaken to isolate the source of Met 5-enkephalin in the 
brain and to see if there are any similarities with proenkephalin A from the 
adrenal medulla or if it is derived from a much bigger preproenkephalin 
containing proenkephalin A and B sequences, such as the original 50,000 dalton 
precursor found in the adrenal medulla. 
2.3. Structure Activity Studies 
In order to design super-agonists much structure activity work has been 
done on the enkephalins with the aim of finding the important functionality 
required for binding to the receptor site. From the earliest work blocking of the 
C-terminal carboxyl group by either dansylation or amidation39 resulted in 
analogues with equal potency. However, nothing more than monomethylation 
could be done on the N-terminal amino group without loosing biological 
activity. The tyrosine in position one was found to be essential. Any tampering 
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activity 39,40. Mono-iodination of the tyrosine phenyl ring gave an analogue (48) 
with only 9-30% activity in vitro whereas the di-iodinated compound (49) had 
an 	exceedingly low potency 41. This was interesting when considering 
radio-iodinated analogues for binding studies to receptor sites. A much better 
method would involve the C-terminal dansylated analogues using fluorescence 
for detection. 
When early workers found the enkephalins to have very low activity in in 
viva assays they soon realised that it was due to the breakdown of the 
pentapeptides by peptidases. Close examination of this degradation by thin 
layer chromatography showed the Tyr-Gly amide bond was cleaved. In an 
attempt to render this bond inacessible to the cleavage enzymes G1y2 was 
replaced by D-amino acids from which arose the analogue (5 0)42 . This 
analogue was equipotent with Met 5-enkephalin in receptor binding but is not 
degraded. Also it showed analgesic properties when injected 
intracerebroventricularly (icy) but no activity when administered intravenously 
(iv). Further work showed that analogues with either D-methionine or 
D-norleucine in position two were even more potent but analogues with basic 
residues (eg.D-lysine) or aromatic residues (eg.D-phenylalanine) in position two 
had diminshed activity. 
Modification in any way of the residues in positions 3 and 4 results in 
analogues with little or no activity. 
Substitution 	of Leu5 	or 	Met 	with 	norleucine 	results 	in 	analogues 	with 
comparable activity 43. 	This 	is interesting 	since it 	questions the need of the 
methionine sulphur atom or the 	s-branching of the 	leucyl side-chain. 	In an 
attempt to protect the amide bond between positions 4 and 	5 Bajusz 	et al 
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increase in biological activity44. Coupled with the results from other 
substitutions (51) evolved as a potent analogue which in viva was 80x stronger 
than morphine 45 on icy administration and in vitro was up to 8x more potent 
than Met 5-enkephalin. This increase in activity was put down to its stability 
towards peptidases and it assuming a different conformation to 
Met 5-enkephalin resulting in favourable transport and or binding properties. At 
first this exceptional activity was thought to be due to the intracyclic amine 
functionality of the proline residue. However, analogues with norvaline in 
position 5 (52,53), where the proline ring is opened and the c&-amino character 
is conserved, resulted generally in an increase in activity46. 
An early observation that Tyr-Gly-Gly-Phe (54) exhibited full enkephalin 
activity 36  led to a whole series of truncated enkephalins. A number of 
tetrapeptide analogues were reported to be potent in both in viva and in vitro 
assays47. (55) and (56) were equipotent with the parent pentapeptides on the 
GPI assay but less so on the rat tail flick test. An evaluation of the data led to 
a series of 25 tripeptides and 5 dipeptides being synthesised and assayed on 
the guinea pig ileum (GPI)48. Tyr-Pro-Phe-NH2 (57), Tyr-DAla-Phe-NH2 (58), 
Tyr-DAIa-Phe-CH20H (59) and Tyr-DPhe-Phe-CH20H (60) had 20-25% activity 
of 	Met 5-enkephalin. Four aromatic alkyl amides of Tyr-DAIa were shown to 
have full enkephalin-like activity on the GPI. Tyr-DAla-phenylpropyl amide(61) 
was found to possess 80% of the potency of Met 5-enkephalin in vitro and is 
equipotent with Tyr-oAla-Gly-Met-NH2 in producing analgesia upon icy 
injection. 
2.4. Opiate Receptors 
When it was first noted that some alkaloid opiates could not displace 
(3HTyr1,Met5)enkephalin (62) from its receptor efficiently and enkephalin could 
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not compete for alkaloid binding sites 49  it was thought that this was due to 
different modes of binding to the same receptor or enkephalin induced 
conformational changes of the receptor50. After further work it was suggested 
that this was due to multiple classes of opiate receptors with differing affinities 
for a given analogue51'52. 
From the results of various bioassays and radioreceptor assays opiate drugs 
were found to be more potent in the GPI test than enkephalin where the 
reverse was true for the rat vas deferens assay52. Thus it was postulated that 
two types of receptors existed, a p-receptor in the ileum and a 6-receptor in 
the vas deferens53. When analogues with Gly2 replaced by a D-amino acid were 
tested on both assays different activity profiles were obtained which is 
consistent with the idea of different classes of opiate receptor. Biological 
studies of recent analogues now consist of testing the compounds on both 
assays as in the case of (52) and (53) where it was also shown that (52) can 
discriminate between the two receptor types54. 
2.5. Conformation 
Since enkephalins are known to compete with drugs at opiate receptors it 
is reasonable to assume that the structural and conformational features of both 
the drugs and the enkephalins will be similar at the active site. The enkephalins 
are thought to have various conformations in solution and in a solid state 
based on theoretical minimum energy calculations 53  and proton 55  and 
carbon-1356 magnetic resonance measurements and X-ray diffraction studies57. 
The relevance of the results from these studies to the actual conformation at 
the active site is not yet known. Indeed from minimum energy calculations the 
preferred conformer of enkephalin does not resemble morphine(63)53. Thus, in 



















measurements and structure activity studies has been used to a limited extent. 
It has been shown that the tyrosine residue corresponds to the tyramine ring A 
moiety of morphine where both the hydroxyl group (equivalent to ring D 
hydroxyl) and the amino group (corresponding to the N-methyl group of 
morphine) of tyrosine are essential for activity. It is thought the tyrosine 
configuration may not have to be exact as long as the hydroxyl-amino distance 
remains fixed 57'58. This slight flexibility within the tyrosine could be induced by 
the two glycines which, through H-bonding, can act as a spacer arm and 
confer several orientations within the molecule. The exact conformation of the 
Phe and the Met (or Leu) is not fully understood except that the Phe is 
essential for biological activity. Maybe it corresponds to ring F found in some 
opiates such as phenazocine (64)57  , but not found in morphine. Hence opiate 
drugs may give an insight to the bioactive conformation of enkephalins but a 
greater knowledge of the receptor must be known before the picture is 
complete. 
2.6. Discussion 
A major reason for the success of much of the work done in the enkephalin 
field is because of the availability to the biologist of large amounts of Leu5-
and Met 5-enkephalin , as well as numerous analogues. As the knowledge of the 
role of enkephalins in living systems, especially in man, increases so does the 
need to be able to make them efficiently. Because of their short sequence and 
the synthetically agreeable amino acids which make up the enkephalins, these 
opioid peptides have been used as examples to test new methodology and 
reagents in peptide synthesis on numerous occasions, to the extent that there 
is 	a review on the subject 59. For our part the presence of tyrosine and 
methionine within the molecule presented an ideal opportunity to further 
evaluate the use of the diphenylphosphinyl group as an N-a-protecting group 60 
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and in carboxyl activation via the carboxylic-phosphinic mixed anhydride 
method61. 
2.6.1. Carboxyl Activation 
The way in which a carboxyl group is activated towards nucleophiles is to 
attach a good leaving group to it which leaves the carboxyl function 
susceptible to attack by any electron rich species (Fig.2.3). Over the years this 
has been achieved in various ways by the use of active esters62, 
carbodiimides63, symmetrical 64  and mixed anhydrides65. Of these methods 
mixed anhydrides result in the fastest acylation of amines. The reaction 
proceeds by the in situ formation of the mixed anhydride from the 
N-ct-protected amino acid and the acid chloride at low temperatures (<-20°C) 
under anhydrous conditions. The amino component is added, usually as the 
salt, and the mixture is stirred for 2-4 hours. The disadvantages of this method 
are: 
The temperature must be kept below -20°C when forming 
the mixed anhydride or else disproportionation occurs. 
Conditions must be scrupulously dry throughout the 
synthesis to obtain high yields otherwise the mixed 
anhydride readily hydrolyses to the starting amino acid 
The nature of the R group is usually a bulky one to direct 
the incoming amino function to the appropiate carbonyl 
group. When the amino acid side chain R is also sterically 
bulky, such as in valine or isoleucine, the two groups are 
believed to crowd the approach of the nucleophile which 
can lead to much slower reactions and significant amounts 
of byproducts are formed derived from the attack of the 
amino function at the other carbonyl centre(Fig.2.4). 
To overcome these problems the carboxylic-phosphinic mixed anhydride 
method was introduced to peptide synthesis61. There are a limited number of 
examples in the literature where the anhydride is derived from the phosphonic 
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exact mechanism of activation. Work studying the stability and reactivity of 
mixed anhydrides derived from phosphinic chlorides has led to the introduction 
of the diphenylphosphinic group (67) (R=Ph,X=O). 31P nmr studies have shown 
the mixed anhydride to be formed instantaneously at 0°C. It is slow to react 
with water, or to disproportionate at room temperature, but reacts rapidly with 
a nucleophilic amine to form an amide bond. Furthermore no byproducts 
derived from the attack of the amino function at the phosphorus centre were 
found. This has been credited to the amino group's greater affinity for the 
carboxyl group rather than the phosphorus centre and the greater bond 
strength of the P-O bond over the C-O bond. A general procedure involves the 
formation of the mixed anhydride at 0°C from the N-a-protected amino acid 
and diphenylphosphinyl chloride with one equivalent of base in methylene 
chloride. Although 31P nmr shows the reaction to be instantaneous a period of 
5-15 minutes is usually employed for activation. The amine component (often 
the methyl ester hydrochloride salt of an amino acid or peptide) is added in 
dimethylformamide (DMF) followed by one equivalent of N-methylmorpholine 
(NMM). In the reaction there is a 10% excess of the anhydride to the amine 
component. The amide bond formation is complete after stirring at 0°C for one 
hour and room temperature for one hour. After a standard work up (see 
experimental) the peptide is isolated in a yield of approximately 80% after 
purification. 
Attempts to increase the yield, by insuring totally dry conditions and the 
use of an inert dry atmosphere, failed to improve upon the yields that had been 
obtained before. Even though all the amine component was used up in the 
reaction, as seen on the tic using ninhydrin for detection, and no byproducts 
were obtained after workup (except diphenylphosphinic acid (68) in the 
synthesis of Z-Gly-Gly-OMe) it was baffling as to why higher yields were not 
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obtained. Results obtained from the application of diphenylphosphinic mixed 
anhydrides to solid phase peptide synthesis66, suggested that the 
diphenylphosphinic acid byproduct was forming a salt with the liberated amine 
component, thus removing the latter from the reaction. To counteract this one 
equivalent of base was added to the reaction mixture after the amine 
component and NMM had been added. The base used was 2,6-lutidine 
(2,6-dimethylpyridine) which was thought weak enough not to abstract an 
a-proton from the amino acid residues but strong enough to sequester any 
diphenylphosphinic acid. Racemization tests on model peptides have yet to be 
completed. An analogous situation to this has been reported in solid phase 
peptide synthesis where symmetrical anhydrides have been used for carboxyl 
activation. After acylation of the symmetrical anhydride the resulting unused 
amino acid forms a salt, in the same way as the diphenylphosphinic acid, with 
the liberated amino component. In this case dilsopropylethylamine (69) was 
used as the base67. 
As a result of the addition of 2,6-lutidine yields of recrystallised dipeptides 
and tripeptides rose to 90-95% in many cases affording pure material (by tic) 
(Table 2.1). This procedure was further evaluated by comparing the synthesis of 
Met 5-enkephalin to an earlier preparation using the same conditions but 
without the extra base68. 
26.2. a-Amino and Carboxyl Protection 
The most widely used protecting group for a-amino protection is based on 
the urethanes , R-O-CO-, where the nature of R can determine the conditions 
of cleavage. As a result a large number of urethane protecting groups are 
available which utilise a wide range of deprotecting conditions. Table 2.2 is a 
list of the more popular ones. However, as a result of acidolytic cleavage of 
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ct-Amino and Carboxyl Protection 
urethanes (which is the case for the majority of them) an intermediate 
carbenium ion is formed. While in some examples this species is very short 
lived , in others such as the benzyloxycarbonyl group (Z) (70) or the tertiary 
butyloxycarbonyl group (Boc) (71) the corresponding carbenium ion is relatively 
stable and can be involved in side reactions with certain amino acids with 
sensitive side chains, in preference to being converted to its breakdown 
products, in this case benzylbromide (72) and isobutylene (73) respectively (eg 
Fig.2.5). The side reactions involve alkylation of the side chains of tyrosine, 
tryptophan, methionine and cysteine. In the case of Boc group the 
corresponding tertiary butyl carbenium ion has been found to alkylate the 
indole moiety of tryptophan in three positions73. With tyrosine, the phenolic 
hydroxyl group is alkylated if it is left unmasked. Therefore it is usually 
protected by etherification (see later). Model studies involving tyrosine in 
cleavage studies of tertiary butyl groups with trifluoroacetic acid have shown 
that the phenyl ring is butylated in the ortho position to the hydroxyl group in 
as much as 1% of the total reaction product74. When using the Z group 
methionine has been found to be the most troublesome residue. Acidolytic 
cleavage using hydrogen bromide in acetic acid can lead to S-benzylation of 
the sulphur, forming a sulphonium salt which decomposes to give the 
S-benzylhomocysteine derivative 75  in preference to reverting back to 
methionine. An alternative to acidic conditions was the use of sodium in liquid 
ammonia. Under these conditions the methionine can demethylate to form 
homocysteine76. The sulphur functionality has also been found to poison 
palladium catalysts used in hydrogenolytic cleavage of the Z group. Although 
the product can be obtained using longer reaction times, the formation of 
ct-aminobutyric acid has been reported to occur77. 
Even though these side reactions only occur in yields of 1-5%, repetitive 
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exposure of the sensitive amino acids, as occurs in a stepwise synthesis, can 
cause a serious lowering of the yield and an increase in impurities, making 
isolation of the final product much more difficult. For the stepwise synthesis of 
Met5-enkephalin the C-terminal methionine would be subjected to the 
deprotection conditions four times and a significant loss of product would be 
envisaged. Although scavengers such as anisole (74), thioanisole (75) or 
1,2-dithioethane (76) can be used to remove the carbenium ions from the 
reaction mixture, the use of an acid labile protecting group which does not 
form any reactive intermediates during deprotection was thought to be more 
advantageous and, as a result of this protecting groups with a phosphinamide 
linkage to the amine component were introduced into peptide synthesis 
(77)78.60 By varying the alkyl or aryl groups attached to the phosphorus the 
acid lability of the phosphinamide bond can be changed. When phenyl groups 
are attached to the phosphorus the resulting diphenylphosphinamide (78) can 
be cleaved by the use of mild acid. The mechanism is believed to be similar to 
that proposed by Harger for the cleavage of the chiral phosphinamide (79) using 
methanolic hydrogen chloride solutions 79  Initial protonation of the nitrogen is 
followed by nucleophilic attack at the phosphorus to form a trigonal 
bypyramidal intermediate (81) which dissociates to give the phosphinate (82) 
with no formation of any reactive intermediates and complete inversion at the 
phosphorus. 	From 	X-ray 	data 	on 	similar 	compounds 
(N,N-dimethyl-P,P-diphenylphosphinamide (83) and N-methyl-N-(2-phenyl-
ethyl)-P,P-diphenylphosphinamide (84)) the geometry of the nitrogen was found 
to be a flattened tetrahedron 80  with the nitrogen lone pair of electrons almost 
in the N-P-O plane whereas in the amide bond of the urethanes the trigonal 
nitrogen lone pair of electrons is orthogonal to the N-C-O plane. Hence the 
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P=O bond results in the nitrogen of the phosphinic amide being much more 
basic than the nitrogen of the corresponding carboxylic amides. 
The optimum deprotection conditions have been reported as six equivalents 
of hydrogen chloride in methanol at 35-40°C resulting in complete cleavage 
within twenty minutes61. This deblocking reaction was followed by tic and 31P 
nmr spectroscopy. Alternative deprotection conditions were used for removing 
the final Dpp group since the C-terminal carboxyl group was deblocked and the 
use of methanolic hydrogen chloride solutions could lead to transesterification. 
Other options available include the use of trifluoroacetic acid in aprotic 
solvents, and acetic acid, formic acid mixtures. In conjunction with other work 
on the deprotection of the Dpp group using hydrogen chloride in 
trifluoroethanol it was decided to further evaluate the use of hydrogen chloride 
in dioxane, water mixtures for Dpp deprotection. 
From the experience of earlier attempts at incorporating the phenyl ester 
function into the methionine residue 68  and the success of using the methyl 
ester for carboxyl protection when introducing the Dpp group 60  it was decided 
to use the methyl ester for C-terminal carboxyl protection. Originally the phenyl 
ester was to be used employing the mild alkaline peroxide conditions for a very 
quick deprotection. However, the introduction of the phenyl ester functionality 
to the methionine residue was fraught with difficulties and no efficient 
synthesis of MetOPh evolved. In contrast the synthesis of MetOMe as the 
hydrochloride salt is well established in the literature 81. Also the use of 
hydrogen chloride in methanol for the deprotection step would not cause any 
transesterification problems. Removal of the methyl ester functionality is easily 
achieved with one equivalent of base at room temperature in 2-6 hours. 
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2.6.3. Side-Chain Protection 
As previously mentioned, the two sensitive amino acids in the 
Met 5-enkephalin sequence are methionine and tyrosine which are prone to side 
reactions during acidolytic cleavage of ct-amino protecting groups. 
Unlike most amino acids which require side-chain protection to eliminate 
byproduct formation this has been found not to be the case for methionine. 
The decision to use side chain protection is often taken by the workers after 
considering the nature, size and properties of the final peptide. If methionine is 
left unprotected the sulphur can be alkylated to form the sulphonium salt 82  or 
oxidised to the sulphoxide83[Met(0)]. Since not all S alkylation is reversible 
64 
this side reaction is often left to be corrected during the purification step. 
However, if methionine is used as the sulphoxide84 the S-alkylation is 
eliminated because of the reduced nucleophilicity of the thioether side chain. 
Either way , there is always some uncertainty as to whether to convert the 
sulphoxide to methionine before or after purification. This problem has been 
somewhat alleviated when Met(0) is used in conjunction with other HF 
cleavable side-chain protecting groups by the use of a 1:3 mixture of HF and 
dimethylsuiphide which will convert Met(0) to Met and cleave most 
benzyl-based protecting groups simultaneously85. 
By using the diphenylphosphinyl protecting group as the ct-amino 
protecting group, which does not form any reactive intermediates during 
cleavage, the need for methionine protection is eliminated and so the thio 
ether functionality was left unaltered during the Met 5-enkephalin synthesis. In 
the work up step a stream of nitrogen bubbles was used to perturb the organic 
and aqueous layers instead of shaking. This was a precautionary step to 






















methionine sulphoxide containing peptides have been found in the crude 
product after work up as seen on thin layer chromatography (tic) or high 
performance liquid chromatography (hplc). 
In the past the tyrosine phenolic hydroxyl group has been protected by a 
benzyl function in conjunction with Boc protection on the ct-amino group86. 
Unfortunately the benzyl group is too labile in the presence of acids or 
nucleophiles and serious losses are incurred during Boc deprotection. HF at 
0°C cleaves the benzyl group in 10 minutes but this was accompanied by 
serious side reactions86. In the presence of trifluoroacetic acid (TFA) and HF 
rearrangements occur to form 3-benzyltyrosine byproducts (Fig.2.7). This 
reaction was originally thought to proceed via intermolecular and 
intramolecular mechanisms since the addition of scavengers such as anisole 
reduces the byproduct formation but does not totally eliminate it. However, 
recent studies have shown that the choice of solvent greatly affects the 
formation of 3-benzyltyrosine derivatives. Deprotections in TFA with scavengers 
can result in up to 10% byproduct formation whereas the same deprotection in 
acetic acid gives no rearranged byproducts but only the deblocked peptide. 
This suggests that the rearrangement occurs only by a intermolecular 
mechanism in which the solvent is an integral factor. To incur greater acid 
stability electron-withdrawing groups were introduced into the benzyl aromatic 
ring. The im-bromobenzyl group (85)87  and the 2,6-dichlorobenzyl group (86)88 
are completely stable in standard Boc deprotection conditions and when 
treated with HF they form the 3-benzyl tyrosine derivative in yields of only 
2-7% in the presence of scavengers. Recently protecting groups based on 
sec-alkyl ethers have been investigated as these were thought to form 
carbenium ions which would readily rearrange to a neutral nonalkylating 








cvclohexyl group (87) has been shown to be suitably stable to Boc deprotection 
conditions, as well as nucleophiles commonly used in peptide synthesis, but it 
is easily cleaved using HF89. Alkylation was found to occur when using neat HF 
but addition of scavengers reduced this to <0.5%. This group has been shown 
to be advantageous over the 2,6-dichlorobenzyl group in the synthesis of 
angiotensin 11 (88)89 and fragments of histones H4 (89) and H3 (90) 0  
A novel way of protecting the phenolic hydroxyl group was the use of the 
o-nitrobenzyl group (91)91.  The group is photolytically cleaved at a wavelength 
of 350nm in 10 to 12 hours at room temperature. This is indeed a very mild 
method of removing the protecting group. However accompanying the 
deprotection there was the formation of a yellow contaminant which could not 
be removed from the product, which might suggest why this group has not 
had widespread acceptance in the literature. 
Due to the success of the previous synthesis of Met 5-enkephalin68 in which 
tyrosine has been used without any masking of the phenolic hydroxyl group 
and the proposal that this hydroxyl group does not undergo side reactions 
during mixed anhydride couplings92, it was decided to leave the hydroxyl 
function unprotected and to further explore the possibility of temporary 
protection during the final tyrosine coupling step. 
2.6.4. Synthesis 
Starting with MetOMe.HCI (92), Met5-enkephalin was made in a stepwise 
manner as shown in Fig.2.8. 
Readily available MetOMe.HCI (92) was coupled to DppPheOH (93) using the 
general procedure outlined in "Carboxyl Activation" with the extra addition of 
2,6-lutidine to yield Dpp-Phe-Met-OMe (94) (82%). Deprotection was carried 
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out at 35-40°C using a methanolic solution of hydrogen chloride and found to 
be complete within 15 minutes. A second deprotection using the same 
conditions at room temperature was also complete after 15 minutes. 
HCI-Phe-Met-OMe (95) could only be isolated as a brown oil and so was 
washed with anhydrous diethyl ether several times. The ether was decanted 
after each wash thus removing the diphenylphosphinic methyl ester byproduct 
(96). The oil was then dissolved in dry DMF and coupled immediately to 
DppGlyOH(97) in the same manner as before. Recrystallisation from chloroform 
hexane mixture afforded Dpp-Gly-Phe-Met--OMe (98) (70%) which was 
deprotected in the usual way to afford HCI-Gly-Phe-Met-OMe (99) (86%) as a 
white crystalline solid, after recrystallisation from methanoi,diethyi ether. 
Coupling 	of 	HCI-Gly-Phe-Met-OMe 	to 	DppGlyOH 	yielded 
DppGiy-Gly-Phe-Met-OMe (100) (60%) as a white solid which proved 
impossible to crystallise in a variety of solvent mixtures. Instead it came out of 
solution as a gelatinous precipitate. Tic and hplc showed the compound to be 
pure and so was used without any further purification for the next coupling. 
Standard deprotection afforded HC1-Gly-Gly-Phe-Met-OMe (101) as an oil 
which was washed with diethyl ether and used immediately in the next step. 
During the preparation of DppTyr(Dpp)OMe (102) following the literature 
procedure68, it was noted that a white solid sometimes precipitated out during 
the aqueous work up. The solid was isolated and shown to be mainly (102) by 
spectral analysis and comparison with an authentic sample on tic. This is not 
surprising since pure (102) is not very soluble in ethyl acetate. in a second 
preparation chloroform was used as the solvent in the organic phase and as a 
result the yield increased from 55%68  to 85%. All further preparations of (102) 
used the modified work up procedure and consistently obtained higher yields 
than previously reported. Following the original method DppTyrOH.DCHA (103) 
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was prepared without incident (75%). Upon liberation of the free acid it was 
found that crystalline DppTyrOH (104) could be obtained by concentrating a 
dried ethyl acetate solution of it, acquired during the acidification of the salt, 
and cooling. Full spectral and elemental analysis showed the product to be 
DppTyrOH.2H20 (105) (90%). This was troublesome when considering 
subsequent mixed anhydride activation since dry conditions are essential for 
the activation. 
For the final coupling (105) was dissolved in dry DMF and dried 4A 
molecular sieves were added in an attempt to remove the water of crystallisation 
Drying time was varied from half an hour to overnight but no significant 
changes in yield were observed. Also in this coupling two equivalents of 
diphenylphosphinyl chloride(DppCl) (106) was used to temporarily block the 
tyrosine phenolic hydroxyl group. Since previous attempts to isolate the bis-
Dpp peptide directly from the reaction mixture resulted in obtaining a mixture 
of bis- and mono Dpp compounds (107,108) together with diphenyiphosphinic 
acid (DppOH) (109) and methyl ester(DppOMe) (96), the usual work up involving 
acid and base washes was employed to afford solely the mono (ct-amino) 
Dpp-peptide. Interestingly a coupling using one equivalent of DppCI gave the 
same mono Dpp peptide (108) in a comparable yield to the previous coupling. 
This would suggest that the phenolic group does not take part in any side 
reactions under the coupling conditions of the carboxylic phosphorus mixed 
anhydride as has been proposed in carbon based mixed anhydride couplings92. 
To study this 	further the reaction of DppTyrOH (105) with 	HClAlaOMe (110) 
using two equivalents of DppCl was followed by 31P nmr in order to examine 
the 	reaction profile. Because 	none of 	the 	intermediates 	can 	be 	isolated, 
following the 	reaction 	by 	31P 	nmr does 	not 	give 	conclusive 	proof 	of 	the 
mechanism 	but 	can only 	support postulated 	mechanisms. 	HClAlaOMe 	was 
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chosen in preference to HCIGIyOMe (111) due its greater solubility in DMF. 
Appendix Ishows the results of this experiment. The anhydride formation is 
predictably instantaneous as seen by the appearence of a signal at 28ppm, 
however there is another signal very close to it . In some reactions DppCl was 
present ten minutes after its addition and the absence of a signal around 
30ppm (which corresponds to the phosphorus of DppOPh (112) and the side 
chain Dpp phosphorus of DppTyr(Dpp)OMe (102)9 would suggest that the 
phenolic hydroxyl group is not blocked. The signal close to the phosphorus 
anhydride signal could be attributable to the Dpp-symetrical anhydride (113) 
formed by the reaction of DppCl and DppOH.(The DppOH could arise from the 
hydrolysis of DppCI by trace amounts of water derived from either the solvent 
or DppTyrOH, due to incomplete drying. If all the water is used up excess 
DppCl will remain). Addition of the amine component in DMF resulted in a 
disappearance of the DppCl signal and the merging and enhancement of the 
signal at 28ppm. The DMF had been distilled and dried but might have 
contained a significant amount of water after being storedover a period of a few 
weeks before needing to be replenished. This would lead to partial hydrolysis 
of the DppCl to give DppOH which would react with the remainder of the 
DppCl to form the Dpp-symmetrical anhydride. No new phosphinamide signal at 
around 21-22ppm was observed which indicates the excess DppCl did not react 
with the liberated amine component of HCI.AlaOMe. This is not surprising since 
the formation of Dpp-phosphinamides takes two hours to be complete. Also, 
when comparing the strengths of the two new bonds formed in the 
phosphinamide and phosphinic acid preparations the P-O bond of the 
phosphinic acid is stronger than the P-N bond of the phosphinamide . Hence 
the phosphinic acid would be the predicted product. A signal at 16ppm appears 
soon after the addition of the amine component and can be attributed to the 
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diphenyiphosphinate anion (DppOi. As the reaction proceeds this signal 
increases with the concomitant decrease of the signal at 28ppm. This indicates 
the mixed anhydride is being consumed in the acylation reaction, the 
symmetrical 	anhydride 	remaining 	unchanged. 	Acylation 	of 
carboxylic-phosphorus mixed anhydrides are usually complete within two 
hours. However in this reaction there remained a signal at 28ppm, several 
hours after the addition of AlaOMe, which slowly decreased over 18 hours. This 
could be explained as the slow hydrolysis of the Dpp-symmetrical anhydride by 
water from the air or solvent. The experiment was worked up as usual and 
yielded a white powder, pure by tic, which was shown to be Dpp-Tyr-Ala-OMe 
(114) by proton nmr. 
The results of this experiment, plus the fact that coupling of 
DppTyrOH.2H20 (105) to HCI-Gly-Giy-Phe-Met--OMe (101) proceeds with similar 
yields using either one or two equivalents of DppCl, tends to suggest that the 
phenolic hydroxyl group does not readily react with DppCi under the conditions 
of 	coupling and can be left unmasked. This is in contrast to previous work 68 
done on Met 5-enkephalin synthesis using Dpp-mixed anhydrides where (107) is 
reported to have been isolated . Clearly a more detailed study is required to 
fully understand what is happening. 
After these preliminary studies (108) was made from DppTyrOH.2H20 and 
HC1-Gly-Gly-Phe-Met-OMe using one equivalent of DppCI. After the usual work 
up the product was obtained by concentrating the dried ethyl acetate solution 
and cooling, resulting in a white preciptate which was pure by tic and hplc 
(61%). 
When comparing this synthesis of the fully 	protected Met 5-enkephalin to 
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2,6-lutidine was not used, this synthesis has produced intermediate fragments, 
and a final product, of a much higher purity. This is exemplified in the final 
coupling by the synthesis of Dpp-Tyr-Gly-Gly-Phe-Met-OMe (108) which was 
originally obtained as a yellow powder after precipitation from a methanol 
solution by the addition of water whereas now it can be isolated as a white 
powder after crystallisation from ethyl acetate. In this case the yields of the 
coupling steps are not significantly greater than those reported in the previous 
synthesis. 
Removal of the methyl ester function was achieved using 2.1 eqivalents of 
NaOH in a DMF water,mixture (2:1) in six hours as shown by tic to yield 
DppTyr-Gly-Gly-Phe-Met-OH (115) (91%). The Dpp group was removed using 
twelve equivalents of a 2M solution of hydrogen chloride in peroxide free 
dioxane,water mixture (2:1) at room temperature. The cleavage was followed by 
31 P nmr spectroscopy and was shown to be complete after six hours. 
HCI.Tyr-Gly-Gly-Phe-MetOH (116) was purified by gel filtration on Sephadex 
G15 eluted with 5% aqueous acetic acid followed either by semi-preparative 
reverse phase hplc or partition chromatography on Sephadex G25 using 
butanol, acetic acid, water mixture (4:1:5) as the eluent. The slow cleavage is 
probably due to the solvent effects and the temperature of the reaction. Further 
work involving different dioxane,water mixtures or a different solvent such as 
2,2,2-trifiuoroethanol, together with varying the concentration of hydrogen 
chloride might prove very useful. 
All nmr data of the larger peptides was obtained on a Bruker WH360 
machine. Decoupling experiments were used successfully to assign all the 
signals. However, it was thought that this could be an ideal opportunity to 
evaluate the use of 2D COSY nmr and as a result 2D spectra of (115) and (116) 
Synthesis 
were obtained (Appendix II). They both show quite clearly all the relevant 
couplings, simplifying enormously the high field region (2-3ppm). Unfortunately 
the 2D spectrum of (116) did not show the ct-CH signal of the tyrosine residue. 





3.1. Isolation and Synthesis 
Substance P (SP) (117) is an undecapeptide found throughout the central 
nervous system (CNS) and in peripheral organs. Over fifty years ago von Euler 
and Gaddum isolated a biologically active principle from the brain and gut93. 
This extract stimulated the motility of the isolated rabbit ileum, even in the 
presence of atropine, demonstrating that the effect was not due to 
acetylcholine. These early studies were carried out using crude acid alcohol 
extracts of the equine brain and intestine, dried to a powder form. The active 
principle became known as "P" (for powder) and later universally accepted as 
"Substance P". Since it was first discovered much work has been done on the 
pharmacological properties of SP but it was not until forty years later that it 
was obtained in a pure enough form to be fully characterised and its structure 
determined, proving it to be a peptide. In the course of an attempt to isolate a 
corticotropin-releasing factor from the bovine hypothalami, Leeman and 
Hammerschlag94 found a peptide showing sialogogic activity. Several of its 
properties were similar to SP and it was suggested that the sialogen might be 
SID 95. The emphasis of the work was changed to the isolation of the peptide 
and by the use of gel filtration, ion exchange chromatography and high voltage 
paper electrophoresis they were able to obtain pure samples. (The purity was 
checked by high voltage electrophoresis 96). Amino acid analysis showed it to 
be an undecapeptide composed of Lys1  Arg1  GIn2 Pr02 G1y1  Leu1  Met1  and Phe2 
with the arginine as the amino terminal residue. All pharmacological properties 
of the peptide were identical to those of SP. The extract was of sufficent purity 
that they were soon able to sequence 5P97 by chymotryptic cleavage, Edman 
degradation and carboxypeptidase treatment, and reported its structure to be 
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Substance p  ArgProLysProClnGlnPhePheGlyLeuMetNH2 
Physalaemin  GlpAlaAspProAsnLysPheTyrGlyLeuNetNll2 
Uperolein  GlpProAspProAsriAlaPhePyrGlyLeuMetNH2 
Phyllomedusin  GlpAsnProAsnArgPhelleGlyLeuMetNll2 
Eledoi sin  GipProSerLysAspAlaPhel leGlyLeuMetNH2 
Kassinin  AspValProLysSerAspclnPheValGlyLeuMetNll2 
Fig..3.1 
Isolation and Synthesis 
Arg-Pro-Lys-Pro-Gin-Gin-Phe-Phe-Gly-Leu-Met-NH2. Two years later Studer 
et a! 98  isolated SP from horse intestine and purified it using established 
procedures 9699,1 	They found the amino acid composition and sequence of 
SP to be identical to the sialogogic peptide hence finally proving von Euler's SP 
and the sialogogic peptide to be the same compound. Chang and Leeman were 
also involved in the first synthesis of SP101, carried out using solid phase 
methodology102. Since then there has been several syntheses via both solid 
phase techniques102'103  and classical solution methods104106. In each case the 
pure product was found to have identical properties to SP extracted from 
natural sources. 
3.2. The Tachvkinins 
SP is in the tachykinin family whose members are found in many 
vertebrates and invertebrates (Fig.3.1). Analysis of the members of this 
family 107109 has shown them to have similar structures and biological 
activities. Common to these peptides is the C-terminal sequence 
Phe-Xxx-Gly-Leu-Met-NH2  which seems to play an important role in their 
activity. In smooth muscle and the secretory organs they all have similar 
activities but the relative potencies do vary considerably. It is not yet fully 
understood how SP or the other tachykinins interact at the receptor sites but it 
has been suggested that there are at least two different types of 
receptors' 0'. This postulation is based upon the differing potencies of the 
tachykinins relative to SP. On one type of receptor, as found in the GPI, four 
tachykinins (physalaemin, SP, eledoisin and kassinin) were found equipotent. 
This type of receptor was called the SP-P receptor because physalaemin was 
usually the most potent , although all four peptides acted at nanomolar 
quantities. The other type of receptor, typified by the rat vas derferens, had a 
rank order of kassinin> eledoisin>> SP=physalaemin and was called the SP-E 
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receptor. However the major difference here was that while kassinin and 
eledoisin acted at nanomolar quantities, SP and physalaemin were used in 
concentrations of micromolar quantities in order to elicit a response. To 
assume there are two subclasses of receptors purely on the basis of the above 
findings is a little naive112 , since accessibility to receptors or different rates of 
inactivation could lead to differences in the relative potencies of tachykinins. 
However, in an attempt to make an analogue which would act specifically on 
one of the sites, and so add more weight to this postulation, Sandberg and his 
coworkers found that if the methionine carboxamide of SP was changed to the 
corresponding methyl ester the resulting analogue was equipotent with SP in 
SP-P systems but there was a large decrease in activity on bioassays of the 
SP-E type 3. As to the presence of these subclasses in the CNS, the picture is 
not so clear. It has been reported that eledoisin is more potent than SP in 
elliciting scratching behaviour in mice 4 and antidipsogenic activity in rats 5, 
suggesting the presence of SP-E sites. However, the specificity of [3H]SP 
binding sites in the rat brain membranes seem to reflect that of SP-P sites but 
SP-E sites would only be expected to have a low affinity for (3HISP and would 
not be detected in binding experiments . There is a good possibilty that both 
subclasses are in the CNS but more work has to be done to make the picture 
clearer. 
3.3. Biosynthesis and Substance K 
Until recently SP was the only tachykinin in mammalian systems but the 
fact that other neuropeptides are known to be present in the peripheral and 
central nervous system and that non-mammalian kassinin and eledoisin are 
more potent than SP in some peripheral actions and central nervous effects 
tends to suggest other, hitherto unknown, tachykinins might be present in the 





Partial sequences of (123) and (124) respectively. 
Substance K (125) llisLysThrAspSerPheValGlyLeuMetNll2  
Neurokinin a (126) HisLysThrAspSerPheValClyLeuMetNH2  
Neurokinin B (127) AspMetHisAspPhePheValGlyLeuMetNH2 
Biosynthesis and Substance K 
originate from the same or similar precursors. It is generally accepted that SP 
is initially synthesised as a large precursor but very little is known about SP 
origin and relationship to other tachykinins. By cloning techniques and 
DNA-sequencing Nawa and his coworkers 116 determined two types of bovine 
brain precursor. One, cL-preprotachykinin (123), was found to have a SP 
sequence within it flanked by two basic amino acids. The other, 
-preprotachykinin (124), also had the SP sequence flanked with two basic 
amino acids but also had a sequence which was very similar to kassinin. This 
sequence was flanked by two basic amino acids and so could be liberated from 
the precursor at the same time as SP. This sequence was called Substance K 
(SK) (125) and it was predicted to be the mammalian equivalent of kassinin or 
eledoisin type of tachykinins. SK is probably a decapeptide since a survey of 
various prohormones suggests that the Lys-Arg pair flanking the peptide 
sequence is generally removed during processing 117, unlike the Arg-Arg pair 
preceding the SP sequence. Later work by Kumura and his coworkers 8 led to 
the isolation of two neuropeptides called neurokinin-c (126) and neurokinin-
(127), from the porcine spinal cord. Neurokinin-ct is a decapeptide with the 
same amino acid sequence as SK. Neurokinin-B is a very similar neuropeptide. 
These new tachykinins have been synthesised by Folkers et a 19 using solid 
phase methodology. Neurokinin-ot was found to have 81% of the activity of SP 
and neurokinin-13 was found to have 65% of the activity of SP but this was 
only based on the GPI assay which is typical of SP-P type receptors. A more 
extensive study has since been carried out by Nawa and his colleagues120. 
After recognising the SK sequence in the bovine brain precursor they 
synthesised SK and two analogues, and tested their biological activity. The data 
presented showed that SK had biological activity perculiar to the tachykinins 
and similar to kassinin. This could be accounted for by the similar C-terminal 
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sequences of the two peptides. When tested on several SP-P type and SP-E 
type receptors SK was more active than SP on the latter type and less active 
on the former. Thus they concluded that SK represents a second type of 
mammalian tachykinin that serves as an endogenous ligand for the SP-E 
receptor and may be mutually related but have different physiological roles in 
the mammalian enviroment. 
3.4. Distribution and Pharmacological Properties 
SP has been found in the central and peripheral nervous system of many 
mammalian species 121,122  In the CNS it has been detected in over thirty parts 
of the brain, the spinal cord and many parts of the brain stem. Large 
concentrations have been found in the mescenphalon hypothalamus 
122-127 
In the peripheral nervous system SP has been found in many varying areas. 
Peripheral tissues such as the skin128, lip129, tongue130 and tooth pulp131  of 
various mammals have all been found to have fibres containing SP. Optic 
nerves and cells in the retina, iris, stroma and the optic nerve itself contain 
SP13233. Many studies, mainly on the rat and guinea pig, have found SP 
containing fibres and cells in varying amounts throughout the gastrointestinal 
tract from the oesophagus, stomach, duodenum, jejunum and ileum to the 
colon and rectum 134 
Since SP is found in many different areas within the body it is not 
surprising that it has numerous pharmacological effects usually dependant on 
location and dose. One of the properties first observed when it was originally 
isolated was its stimulating effect on most smooth muscle layers in the 
gastrointestinal tract. It has been found to contract all segments of the small 
intestine in many mammalian and cold blooded species. The relative effect of 
SP is paralleled with its natural abundance within these segments. There is a 
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dose dependant contractile effect in circular smooth muscle of the cat 
oesophagus, and the fundus and corpus of the guinea pig stomach, but not in 
the longitudinal muscle of the fundus and corpus. Interestingly, there is also a 
greater density of SP positive fibres in circular smooth muscle than in 
longitudinal muscle of the rat stomach135'136. In contrast the isolated circular 
muscle of the guinea pig ileum does not evoke any contractions at low 
concentrations 137  whereas the isolated longitudinal muscle of the guinea pig 
ileum evokes a tonic contraction with doses as small as 0.7pmo1138. From the 
gastrointestinal sphincter to the ileum there is an increase in its maximal effect 
as there is also a similar rise in SP concentration in these segments139. 
SP stimulates secretion in the salivary glands and the pancreas140. In vivo 
and in vitro experiments on the dog, rat, guinea pig and hamster have shown 
an increase in salivary flow from the mouth and nose when SP is injected 
intravenously94'141. The dose dependant effect is a direct action on the salivary 
glands as it is not blocked by atropine (128), propanolol (129) and 
phenoxybenzamide (130) which would prevent any response due to 
acetylcholine (131) or histamine (132) released by SP. From in vivo and in vitro 
experiments in the dog SP has shown to stimulate secretion of pancreatic 
juices in the exocrine pancreas by as much as 160%142.  Little is known how SP 
is involved in this effect from the limited information available. The presence of 
SP in the central and peripheral nervous system led several workers to think 
that SP was involved in the transmission of pain. Early work showed that 
introduction of SP onto neurons in the spinal cord caused an increase in the 
firing rate of cells that are also excited by noxious stimulii, which tended to 
suggest that SP was directly involved143. More recent studies seem to show 
that the involvement of SP in pain transmission varies with its location in the 
nervous system. In the sympathetic ganglia SP has been shown to be directly 
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involved as it is released from synapses in the prevertebral ganglia and 
generates noncholinergic, slow excitatory postsynaptic potentials144. Similar 
effects have been shown to occur when SP has been found in neurons within 
the spinal cord 145. However, other evidence has tended to suggest SP might 
have a role as a neuromodulator. Removal of up to 60% of SP from the 
trigeminal nucleus caudalis by neonatal treatment with capsaicin in the rat did 
not alter the proportion of neurons responding to noxious and non-noxious 
stimuli146. This would suggest that SP is not the only compound responsible 
for pain transmission. Other peptides such as somatostatin and vasoactive 
intestinal polypeptide have been found in small sensory neurons and until their 
exact role is known SP cannot be assigned as the sole transmitter of 
nociceptive information. 
The possibility of SP being an analgesic was first proposed by Stewart 
147 
who reported long lasting analgesia in mice (using the hot plate test) after 
intracerebroventricular and intraperitoneal SP injections. This effect which was 
prevented by naloxone was confirmed by later work with mice and rats148'149. 
However, some other authors found no analgesia, if anything a decrease in 
reaction time to the hot plate test, under apparently the same conditions150151. 
These contradicting results of SP are apparently dose dependant. Small doses 
of SP (<4pmol administered to the lateral ventricle) produce naloxone 
dependant analgesia probably by releasing endogenous opioid peptides. Larger 
doses (>40pmol) give rise to hyperalgesia effects by stimulating neuronal 
activity in nociceptive pathways. 
Since positive fibres and cells are usually associated with blood vessels all 
over the body it is not surprising that injections of SP can change the dynamic 
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to be a very potent vasodilating compound. Close arterial injections causes 
vasodilation in the adipose tissue and skeletal muscle152. Intravenous injections 
in dog increases the blood flow in most vascular beds such as the skin, 
skeletal muscle and small intestine153. Intravenous injections in man causes a 
similar increase in blood flow with red flushing of the skin around the face and 
neck 154.  in circular smooth muscle than longitudinal muscle of the rat 
stomach 135,136 
35. Substance P Analogues 
3.5.1 Structure Activity Studies 
From early nmr evidence SP and biologically active C-terminal fragments 
were found to contain a hydrogen bond between one of the Gin residues and a 
carboxyl in the C-terminal region and also one of the phenylalanines has a 
constrained conformation 155. These properties were not found to be present in 
shorter inactive fragments. Thus it was concluded that SP had a U-shaped 
peptide backbone in which probably the Phe7 side chain had the constrained 
orientation (Fig.3.2). This has since been backed up by conformational energy 
calculations 156  which suggested that favoured bioactive structures are 
stabilised by interactions between the C-terminal residue and the Gin  or the 
Gin  residues, and by molecular structures of SP based on a semi-empirical 
conformational analysis 157  which suggests a bend in the peptide backbone near 
Phe7 and Leu10. Recent work involving nmr and circular dichroism (cd) studies 
suggests that in water SP has many complex conformations as well as 
aggregation with itself 158.  However in methanol SP adopts one major 
conformation where the Arg-Pro-Lys portion is very flexible, the 
Pro-GIn-GIn-Phe-Phe portion is part of a ct-helix and the Gly-Leu-Met is 
orientated so that there is some interaction with the Gin 5,6  primary amides. 
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Taking all these reports into account the overall picture is that SP and active 
fragments have a U-shaped peptide backbone with a conformationally 
constrained Phe7 which could be essential for fitting and binding to receptor 
sites. Whether this is the actual conformation of SP at the receptor site or 
merely a solvent induced conformation cannot be determined from the above 
work. 
This proposed bioactive conformation of SP would explain why shorter 
C-terminal fragments have comparable biological activity which would seem to 
question the need for the N-terminal tetrapeptide 159. However there are several 
properties of SP which have been attributable to this area of the peptide. 
Subtitution of 0-amino acids in the C-terminal region of C-terminal fragments 
removes the hydrogen bonding which results in loss of biological activity160. 
D-amino acid substitution in the C-terminal region of SP results in analogues 
with no hydrogen bond but with a significant amount of biological activity. This 
would suggest that the N-terminal tetrapeptide stabilises the bioactive 
conformation. Other studies have shown that the N-terminal tetrapeptide also 
stabilises SP against enzymic degradation 161.  C-terminal hexa- and 
hepta-peptides were shown to have comparable activities to SP but in the 
presence of rat brain homogenates, which contain peptidases, had a much 
shorter lifetime. Finally SP induced histamine release has been attributed to the 
N-terminal tetrapeptide 162.  Whilst C-terminal fragments are devoid of 
histamine-releasing activity, the N-terminal tetrapeptide did cause histamine 
release and the effect was increased when it was coupled to various 
C-terminal fragments163. 
From the little work done on studying positions 5 and 6 it can be seen that 
the amide functionalities of both GIn residues do not participate in maintaining 
42 
Structure Activity Studies 
the bioactive conformation. The biological activity of analogues with L-alanine 
substituted in either position 5 or 6 (134,135) was similar to SP on in vivo and 
in vitro preparations 164. C-terminal hexa- and heptapeptides with an N-terminal 
pyroglutamic acid gave increased and equal biological activity (135,136), 
respectively 165. An analogue with N,N-dimethylglutamine in position 6 (137) had 
equal biological activity to SP. All these analogues have little or no amide 
functionality on the side chain but all retain full biological activity. Phe7 is an 
interesting position in that it occurs in all tachykinins and is thought to be 
directly involved with binding to the receptor. From the work that has been 
done replacement of the Phe with a neutral aliphatic amino acid (Leu or lie) 
drastically reduces the biological activity166. Changing the nature of the 
aromaticity of the phenyl ring by introducing electronegative and 
electron-donating substituents in the para-position did not change the 
biological activity167. Substitution of Phe with cyclohexylalanine (CHA) resulted 
in only a small drop in biological activity. These results suggest the aromatic 
character and planar structure of the phenyl ring are not essential for high 
biological activity 166. The phenyl side chain in position 8 has been found not 
essential for biological activity . Substitution with any neutral amino acid does 
not result in a loss of activity168. Interestingly, SP (117) and physalaemin (118) 
have aromatic residues in this position and eledoisin and kassinin have 
aliphatic residues in this position, hence analogues with a selectivity for SP-P 
or SP-E receptors could be envisaged with appropiate substitutions in this 
position. However, this was found not to be the case when [Ala8]SP 1  (138) 
was tested on the GPI assay (SP-P type receptors) or the rat vas derferens 
(SP-E type receptor). 30-40% of the activity of SP was observed on both 
assays 168. G1y9 is important due to the bend in the peptide backbone at this 
position. Analogues with N-methylglycine or L-alanine have equipotent 
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biological activity168'169 but D-amino acid substitution results in analogues with 
no biological activity 170 Hence, G1y9 is not important as a special 
conformational element (since L-amino acid substitutions do not destroy 
biological activity) but the glycine does not adopt a pseudo D conformation. 
Substitution of Leu10 by Ala results in a slight loss in biological activity 
168  but 
unfortunately no other work has been published about this position. Originally 
substitution of Metil  with most L-amino acids resulted in a loss of biological 
activity on the GPI assay. Further studies on changing the nature of the 
methionine side chain by introducing other hetero atoms (O,C,Se) and 
branching showed only one analogue, in which Se replaces the 5, to have 
biological activity171. Thus it was suggested that the lipophillicity and van der 
Waal's radius at the 6 position might be the active elements. Substitution of 
Leu for Metil  has recently been shown to increase the antagonistic activity of 
known antagonists even though it has no agonist activity as it was originally 
discovered (see later for more detail). The C-terminal amide has been shown to 
be essential for activity. SP111C00H (139) is completely devoid of activity 
172 
whereas SP 1COOMe (140) shows equipotent activity with SP on SP-P type 
receptors but no activity on SP-E type receptors 3. Also (140) has a greater 
activity than SP in the CNS173. 
3.5.2. Enzyme Resistant Analogues 
Many analogues of SP have been found to have equal or greater biological 
activity but have a short lifetime in in vivo preparations. This is equally 
applicable to antagonists where analogues have been made with antagonistic 
activity , as seen in in vitro assays, but are useless in in vivo experiments due 
to rapid enzymic degradation134. With this in mind work has been done to 
design enzyme resistant analogues. Purified extracts of endopeptidases from 
within the brain have been shown to cleave SP at the Gln6-Phe7, Phe7-Phe8 
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and Gly9-Leu10 amide bonds. A membrane-bound endopeptidase, thought to be 
involved in the removal of SP after synaptic release, has been isolated and 
shown to degrade SP but not other neuropeptides174. In order to stop the 
amide bond cleavage, analogues with N-methyl amino acids in the relevant 
positions have been made. These analogues were resistant to cleavage at the 
aforementioned bonds168 but the N-terminal fragment was cleaved175. 
Therefore analogues based on C-terminal hepta- and hexa-peptides with a 
N-terminal pyroglutamic residue were tested. [G1p5,(Me)Phe8,(Me)01y9] SID 5-11 
(DiMe-C7) (141) was equipotent with SP in the rat brain but completely 
resistant to the SP-degrading membrane-bound peptidase16975. Similarly, 
[Glp6, (Me)Phe7,(Me)Leu 0]SP61  (142) had the same biological activity as SP 
but was resistant to degradation by pepsin, chymotrypsin, papain and 
thermolysin 76 
3.5.3. Antagonists 
Work to date, on designing and synthesising SP antagonists has been based 
on modifying the peptide backbone by D-amino acid substitution. This proved 
very useful when key amino acids of lutenizing hormone releasing hormone 
(LHRH) were replaced by D-amino acids to yield a potent antagonist 177. Early 
work centred on structure activity studies using single D-amino acid 
substitutions in order to form an analogue with no agonist activity. As a result, 
D-amino acid substitutions in C-terminal fragments and SP in positions 2,7,8,9 
and 11 gave promising results. [o-Phe7]SP 	1(143) and [o-Pro2]SP 1(144) are 
full length analogues with no agonist activity178. Using the results of the LHRH 
work D-Trp was substituted into C-terminal fragments but only one analogue, 
[Arg6,D-Trp101SP11 (142), had no agonist activity, as well as marked antagonist 
activity1 79• 
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To design analogues with antagonist activity D-Trp was substituted into two 
or three key positions within SP. From the many full length analogues originally 
made [DPro2,DPhe7,DTrp9]SP1 1(146)  and [oPr02,oTrp7'9]SP1 -11(147) were found 
to have antagonistic activity with weak agonistic effects180. Multiple 
substitution of oTrp in C-terminal fragments of varying lengths led to the 
developement of several analogues with increased antagonistic activity. 
[oPro4,oTrp7'9]SP4 1(148),  an analogue very similar to [DPrO2,DTrp79]SP1 1(147) 
but much more potent, was also found to have no agonistic activity181. 
[oPr04,oTrp7'9'10]SP411  (149) with oTrp substituted in all the key positions has 
3-6 times the antagonistic activity of its predecessor without any agonist 
effects. It has been shown to be active against the stimulatory effects of SP (in 
the GPI) and the inhibitory effects of SP (the rat blood pressure, the rabbit 
isolated heart and the dog carotid artery 181). 
In search for an antagonist with no agonist activity it has been found that 
0-amino acid substituted analogues with Met 11 replaced by Leu show enhanced 
antagonistic activity with no agonist effects. This was first noted when 
[DArg2,DTrp7'9,Leu 1]SP1 -11(150) was found to have increased antagonistic 
activity 182,  sometimes as much as a 100-fold, but no agonistic activity. Recent 
developments of this analogue, mainly by small changes in the aromaticity of 
the side chain of position 7, has led to twenty more similar analogues with 
increased antagonistic activity183. (Fig.3.3 shows some of the more potent 
analogues). C-terminal fragments based on [oPro4,oTrp7'9]SP411  and 
[oPr04,oTrp7'9'10]SP411  with Met" replaced by Phe, Leu and Nie have also been 
made and shown to have greater antagonistic activity over their predecessors, 
without a trace of agonistic activity184. All of them have been shown to be a 
more potent antagonist than [oArg2, DTrp7'9,Leu11]SP1 11  in various in vitro and 














To date there are several antagonists available specific only to SP for 
biological testing. However, their antagonistic activity and potency are not of 
sufficient magnitude for them to be considered as models for drug design and 
so they can only be used as a basis of future work. 
3.5.4. Cyclic Analogues of SP 
Since the active conformation of SP was thought to be a U-shape with 
some interaction (ie H-bonding) between the C-terminal carboxamide and the 
GIn's in positions 5 and 6 cyclic analogues were made in an attempt to fix this 
shape , so as to conserve the bioactive conformation in different solvents and 
media, which would hopefully enhance agonistic activity. 
To date there havebeen two approaches to the synthesis of such analogues. 
The first substitutes appropiate amino acids, where the connection is to be 
made from, with cysteine and then forms a disulphide bridge to make the 
link 	as  in the compounds listed in Fig.(3.4). Surprisingly no activity was 
amount 
found in compounds (151-153) and (154,155) only possessed a very smallof 
agonist activity. Other methods of forming a link included an amide bond 
linkage between glutamic acid and lysine in the appropiate positions 187  and 
spacer arms made up of E:-amino caproic acid units188. With the latter method 
the distance between positions 5 (or 6) and 11 could be varied (Fig.3.5). These 
analogues were also found to be weak agonists or to have no activity at all. 
Hence it seems that the SP receptors must recognise SP in an extended form 
and bind to it in a zipper like fashion, after which its conformation may change 
to the U-shape for binding to the active site. If this was so the linkage of 





-- RECEPTOR v_v 
V 7 
RECEPTOR V V 
- 	 - 	 I 
 
 
Zipper Type Binding 
 
Cyclic Analogues of SP 
3.6. Discussion 
As part of a programme, aimed at the synthesis and evaluation of potential 
SP antagonists, being carried out within our research group, this work has 
involved the preparation of analogues which might disrupt the biosynthesis of 
the C-terminal amide. In conjunction with other work, C-terminal fragments of 
SP and SP-COOH were also synthesised. It was thought that biological activity 
might be as a result of favoured structural conformations which could be 
observed through interpretation of nmr data. In addition to this the synthesis 
and development of potential reagents for peptide synthesis (such as new 
phosphorus activating groups, a novel method for binding peptides to solid 
supports and the use of spacer arms in solid phase peptide synthesis), was 
carried out to varying degrees. 
3.6.1. Peptide Synthesis 
The synthesis of SP C-terminal fragments and extended fragments was 
seen as another opportunity to further demonstrate the use of the Dpp group 
as an acid labile amino protecting group and organophophorus reagents as 
activating groups. Of the amino acids present within the C-terminal sequence 
of SP methionine is the only one which might be considered for side chain 
protection. With it being at the carboxy terminus it would be vulnerable to 
attack by any reactive intermediates formed during the repetitive deprotection 
of ce-amino protecting groups. (This could be a problem if Boc was used as an 
a-amino protecting group). However, with the use of Dpp as the a-amino 
protecting group which does not form any reactive intermediates during 
deprotection, and the success of the Met 5-enkephalin synthesis in which there 
is also a C-terminal methionine residue, it was decided not to mask the 
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Peptide Synthesis 
From previous work it had been shown that the Dpp group can be removed 
from a peptide with a C-terminal amide without any transesterification189. 
Standard conditions for such a deprotection are six equivalents of hydrogen 
chloride in methanol or trifluoroethanol at 0°C for six to eighteen hours. These 
reactions have been monitored by tic and 31P nmr spectroscopy. The long 
reaction times for complete cleavage led us to use the methyl ester for 
carboxyl protection which enabled us to use the standard deprotection 
conditions outlined in the previous chapter. Removal of the methyl ester was 
as before using one equivalent of NaOH to give the free acid and where 
necessary the methyl ester could be amidated using a saturated solution of 
ammonia in methanol to produce the C-terminal amide. 
For the stepwise synthesis of some of the fragments the procedure was the 
same as that employed for the synthesis of Met 5-enkephalin. The synthesis of 
two of the larger analogues involves a fragment condensation between a 
pentapeptide and a tetrapeptide. Fragment condensations allows the synthesis 
of large peptides to occur on a larger scale without the need to make vast 
amounts of smaller fragments and starting materials, as is required for 
stepwise synthesis. A problem associated with fragment condensations is 
racemization of the activated residue.This can occur in two ways, either by 
base abstraction of the ctC-H proton or by formation of a 5(4h)-oxazolone. 
Activation of the carboxyl function is usually achieved by an increase in the 
thermodynamic activation of the acyl function which results in an increase in 
the lability of the ce-proton. This proton is then prone to abstraction by any 
bases present. However, strong bases usually exist as salts and in the presence 
of the activated carboxyl group the nucleophilic amino component will always 
take part in the preferred aminolysis. As for the 5(4/)-oxazolone formation this 
reaction is dependent on many factors namely the solvent, activating group, 
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bases present and the nature of R and R (Fig.3.6). 
The applicability of the Dpp group and the Cpt group to fragment couplings 
has recently been explored. Initial results on the use of the Dpp group suggest 
that it is too active, rendering the ctC-H very labile as well as promoting 
formation of the 5(4h)-oxazolone. Experiments have shown racemization to 
occur from 6% to as much as 42% 
68,190  A more detailed study on the use of 
the Cpt group in fragment couplings has shown that when used with 
N-ethylmorpholine (156) as the base in either methylene chloride or DMF only 
1.5% racemization occurs191.The proposed fragment condensation involved the 
activating of a glycine residue on the N-terminal fragment , which overcomes 
the problem of racemization of the activated residue. Formation of oxazolones 
results in lower yields and the unused liberated amines can be involved in 
minor side reactions lowering the yield still further and causing difficulty in 
isolation of the pure product. Therefore CptCl (157) was used under the 
conditions proposed by Ashton for fragment coupling condensations190. 
3.62. SP Extended Analogues 
Since it is known that amidating enzymes exist which oxidatively convert 
C-terminal glycines to an amide functionality when processing peptides from 
their precursors (Fig.1.3), and such a process has been postulated for SP, it was 
considered that the synthesis of extended SP analogues with residues which 
would protect the Met-Gly12 bond from amidation might provide useful 
antagonists. As the C-terminal heptapeptide fragment of SP has been shown to 
have comparable activity to SP itself, but does not have the histamine releasing 
properties of the N-terminal tetrapeptide, all the analogues are based on this 
sequence. Originally, before the mechanism of amidation was fully understood, 






OH 	(17 0) 
JN1e (iso) 











SP Extended Analogues 
glycines had reduced amidation. So, applying this to the SP case led to the 
synthesis of the fragments in Fig.3.7 all possessing two extra glycines on the 
C-terminus. This would result in G1y13 being involved in an amidating step 
resulting in a glycine extended peptide amide whose biological activity in SP 
assays is not known, but it may be an antagonist to SP. Thus any drop in 
agonist activity or the presence of antagonist activity might be due to the 
interaction of the extended analogue with SP amidating enzyme, thus disrupting 
the SP biosynthetic pathway. Future work in this area involves the 
strengthening of the Met"-Gly12 linkage and irreversible binding of the 
analogue to the amidating enzyme. This is hoped to be accomplished by 
replacing the glycine-N for C and synthesising glycine analogues which mimic 
possible reactive intermediates which could bind irreversibly to the active site 
in the amidating enzyme. 
The smaller SP extended C-terminal fragments were made in a stepwise 
manner as shown in Fig.3.8. This work was started before the advantages of 
adding an extra equivalent of 2,6-lutidine were known. Otherwise the coupling 
and deprotection procedures were identical to those used for the synthesis of 
Met5-enkephalin. Thus DppMetOH (158) was coupled to HBr-Gly-Gly--OMe 
(159)190 to yield crude DppMet-Gly-Gly-OMe (160) as a brown foam. 
Purification was achieved by dry flash chromatography using a stepwise 
gradient of 1% increments from 0-5% methanol in chloroform to give a white 
foam, yield 93%. Deprotection of the Dpp group gave a white powder after 
work up which was recrystallised from methanol-ether mixtures to give 
HCI.Met-G(y-Gly-OMe (161) in 85% yield. (161) was coupled to DppLeuOH (162) 
to give DppLeu-Met-Gly-GlyOMe (163) in a 70% yield after purification by gel 
filtration on Sephadex LH20 with methanol as the eluent or dry flash 
chromatography using the same elution conditions as before. (163) with the 
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two C-terminal residues of SP was thought big enough to be recognised by 
the amidating enzyme and so a portion of it was saponified to give 
DppLeu-Met-Gly--GIyOH (165). After workup (165) was obtained impure and was 
purified by wet flash silica chromatography (9:1,CHCL3:MeOH) to give the pure 
product in a final yield of 84%. Attempts at recrystallisation gave only 
gelatinous precipitates. Deprotection of (163) took two hours at room 
temperature to yield HCI.Leu-Met-Gly-GlyOMe (165) as a white solid which was 
very hygroscopic. No further attempts were made to isolate and characterise 
this solid but instead after several washes with anhydrous diethyl ether and 
drying in a dessicator over phosphorus pentoxide overnight it was coupled in a 
DMF solution to DppGlyOH (97). Initially this was a troublesome coupling giving 
a crude product which was insoluble in ethyl acetate and so was applied to a 
Sephadex LH20 gel filtration column using DMF as the eluent. The product 
containing fractions were pooled to give a slightly impure product in about 
60% yield, which after purification on silica resulted in a large loss in weight of 
material to give (166) in yields of round 40%. Changing the solvent from 
dichloromethane (DCM), DMF mixtures to DMF only, did not seem to make any 
difference on yield or purity. When this preparation was later repeated using an 
extra equivalent of 2,6-lutidine with DMF as the sole solvent the final yield was 
increased to 55% but no improvement on this could be made. Surprisingly 
saponification of (166) using the same conditions as for (164) took thirty 
minutes to give DppGly-Leu-Met-Gly-GlyOH (167) which was purified on a 
Sephadex LH20 column with DMF as the eluent in a final yield of 61%. Dpp 
deprotection of (166) proceeded smoothly in thirty minutes at 35-40°C 
affording a white hygroscopic powder of (169) which was stored in vacuo over 
phosphorus pentoxide until needed. HCI.Gly-Leu-Met-Gly-GlyOMe (168) was 
coupled to DppPheOH(93) in the usual manner without any incident affording a 
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crude product which was soluble in ethyl acetate and worked up as usual. 
DppPhe-Gly-Leu-Met-Gly-GlyOMe (169) was obtained as a white powder after 
precipitation from ethyl acetate by light petroleum ether in a 73% yield. 
Saponification of (169) to DppPhe-Gly-Leu-Met-Gly-GIyOH (170) was complete 
after four hours. The product was obtained as a white powder in a 68% yield. 
From other work being done on structure activity studies of SP C-terminal 
fragments Glp-Gln-Phe-Phe-GlyOH (171) was available in relatively large 
amounts. Therefore the synthesis of Glp-Gln-Phe-Ptie-GIy-Leu-Met-
Gly-GlyOMe (172) and GIp-GIn-Phe-Phe-Gly- Leu-Leu-Gly-GlyOMe (173) was 
adapted to include a fragment condensation. The overall scheme is shown in 
Fig.3.9. Leucine was incorporated into position 11 after noting the reported 
enhanced antagonistic activities of analogues resulting from the work of 
Folkers 150  and Regoli184. DppLeu-Met-Gly-GlyOMe (163) was prepared as 
before without incident. DppLeuOH was coupled to HBrGly-GlyOMe to yield 
DppLeu-Gly-GlyOMe (174) as an off-white foam after the usual aqueous work 
up. This was immediately deprotected using the standard procedure to give 
HCILeu-Gly-GlyOMe (175) in a yield of 64% after recrystallisation from 
methanol. Coupling of (175) to DppLeuOH (162) gave DppLeu-Leu-Gly-GIyOMe 
(176) as a white powder which was slightly impure after work up but could be 
purified by gel filtration on a Sephadex LH20 column eluted with methanol or 
by dry flash silica chromatography using the elution conditions as for (160). 
Either way produced the product in a yield of 73-80%. Attempts at isolating the 
hydrochloride salt of the deblocked compound (177) gave a white hygroscopic 
powder 	which 	proved 	troublesome 	to 	handle. 	Therefore 
HCILeu-Leu-Gly-GlyOMe (177) was prepared prior to the coupling step. Initial 
fragment couplings of (171) to (165) or (177) gave poor yields of the final 
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SP Extended Analogues 
-20°C whereupon one equivalent of CptCl in methylene chloride and 
N-ethylmorpholine (NEM) were added dropwise. After fifteen minutes a solution 
of (165) in DMF and NEM are added and stirring was continued below -20°C for 
one hour and at ambient temperature for one hour. A few drops of water were 
added to destroy unreacted mixed anhydride and the solvent was removed. The 
residue was redissolved in a minimum of DMF and applied to a Sephadex LH20 
gel filtration column (2.5x9Ocm) eluted with DMF. The product was isolated and 
passed through a second Sephadex LH20 column (lx50cm) again eluted with 
DMF. Using this procedure (172) and (173) were prepared in 22% and 26% 
yields respectively (Ca. 70% based on recovered starting material). The addition 
of one equivalent of 2,6-lutidine increased the yield of (173) slightly from 26% 
to 31%. In comparison coupling of (171) to (165) or (177) using the DCCI 
method with HOBt as a catalyst gave the product in higher yields of 67-70% 
consistently but no starting material was recovered. Based on the results of 
other workers the coupling time was increased from one hour at room 
temperature to five hours. The resulting yield of (172) increased to 51% (69% 
based on recovered starting material). Further work is currently in progress 
evaluating and optimising conditions for fragment condensations of model 
compounds. 
3.6.3. C-terminal Fragments of SP 
In an attempt to observe structural conformations within a molecule by nmr 
and relate any observation to biological activity it was proposed to make the 
C-terminal fragments of SP from SP 
5-11  to SP1011  with both amide and 
carboxyl termini. Fig.3.10 shows the list of fragments that have been made to 
date. The C-terminal fragments were prepared as shown in Fig.3.1 1. DppLeuOH 
(162) was coupled to HCI.MetOMe (92) in the usual manner to give 
DppLeu-MetOMe (178) in 80% yield after recrystallisation from ethyl acetate, 
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petroleum ether mixtures. Deprotection of (178) using a methanolic solution of 
hydrogen chloride took 2 hours at room temperature as shown by 31P nmr. 
Removal of the solvent afforded HCI.Leu-MetOMe (179) as an oil which did not 
crystallise out from several solvent systems and so was washed with ether 
several times and used in the next coupling. The reaction of DppGlyOH (97) 
with (179) using standard conditions proved very troublesome. After aqueous 
workup DppGly-Leu-MetOMe (180) was isolated as a brown powder which 
would not crystallise. Initial attempts at purification involved gel filtration on 
Sephadex LH20 with methanol as the eluent, followed by droplet counter 
current chromatography using a MeOH, Buffer P. CHCI3,CCI4 solvent system 
(Buffer P= 15m1. of acetic acid and 8.5g of ammonium acetate per 500ml of 
water) resulting in pure (180) in a 23% yield. A repeat experiment utilising dry 
flash chromatography for the purification step gave the product (180) in 51% 
yield. Treatment of (180) with 1.1 equivalents of NaOH in a dioxan water 
mixture removed the methyl ester in four hours to give DppGly-Leu-MetOH 
(181) (85%). (180) was stirred with a saturated methanolic ammonia solution 
overnight to give DppGly-Leu-MetNH2 (182) (71%). Removal of the Dpp group 
from (180) gave the product HCI.Gly-Leu-MetOMe(183) as an oil which was 
washed with diethyl ether accordingly and used in the next coupling step 
immediately. Coupling of DppPheOH(93) to crude (183) afforded 
DppPhe-Gly-Leu-MetOMe (184) in a 71% yield after the usual aqueous work up 
and precipitation from ethyl acetate by light petroleum ether. Saponification of 
the methyl ester was complete after five hours to yield 
DppPhe-Gly-Leu-MetOH(185) (77%). Amidation of (184) using a saturated 
methanolic ammonia solution was complete after stirring overnight (as seen by 
tIc) to give DppPhe-Gly--Leu-MetNH2  (186) in a 70% yield. Deprotection of (184) 
as previously described gave HCI.Phe-Gly-Leu-MetOMe (187) as a hygroscopic 
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white powder which proved difficult to handle. Hence it was immediately 
coupled to DppPheOH (93) under standard conditions to give 
DppPhe-Phe-Gly-Leu-MetOMe (188) (48%). The low yield might be due to using 
methylene chloride as a cosolvent and the use of DMF as the only solvent, 
which is known to give increased yields, might prove useful. Amidation, using 
the conditions previously mentioned, was complete after three days. The 
ammonia was replenished every twenty four hours by bubbling ammonia gas 
into 	the 	solution, 	cooled 	to 	-15°C, 	for 	45 	minutes. 
DppPhe-Phe-Gly-Leu-MetNH2 (189) was obtained as a white powder in a 66% 
yield. 
Since the full list of SP fragments and analogues has not yet been 
completed a detailed nmr study involving nOe experiments, solvent perturbation 
and determination of temperature coefficients is yet to be carried out. However, 
analysis of the proton nmr of the compounds made to date shows the NH-cCH 
coupling constants of all the amino acids except glycine to be 7.5-8.5Hz which 
is in direct agreement with reported NH-aCH J values of SP and C-terminal 
fragments 158,192.  This is consistent with a a value of -1480 to -1580 or from 
-840 to -940. The vicinal coupling constants of the glycines' NH-cCH2 is 
around 5.5Hz indicating an angle a close to 180°. This also is in direct 
agreement with reported J values of glycines in SP and C-terminal fragments. 
However, using DMSO as the solvent ruptures any inter- or intramolecular 
hydrogen bonding therefore these figures may represent time averaged values 
derived from numerous constantly changing conformations. More work is 
required to ascertain the conformational properties of these compounds and to 
see if the presence of the Dpp group has an inductive effect on the tertiary 
structure. 
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AGONIST ACTIVITY 	 ANTAGONIST ACTIVITY 
E.P.M.R. 
BIOASSAY 
G.P.l. R.C. R.S.C. G.P.I. H.C. R.S.C. 
41530 Dpp. 	SP(7-11) 2,500 1,000 N.T. N.T. N.T. N.T. 
41531 Dpp. SP-(.11)OMe. 
[Trp'9]SP-(6-1i) 
>10,000 >300 N.T. N.S.E. N.T. 
1532 Dpp. 
Dpp. 	[Trp6'9]SP-(6-11).OMe 
>10,000 >300 N.T. N.S.E. N.S.E. N.T. 
1533 >10,000 >300 N.T. N.S.E. N.S.E. N.T. 
59673 Dpp.Phe.Phe.Gly.OMe. >10,000 >300 >300 Non N.S.E. N.S.E. 
Comptitive 
596714 Dpp.Phe.Gly.Leu.Met.OH. >10,000 >300 >300 N.S.E. N.S.E. N.T. 
59675 Dpp.Gly.Leu.Met.N 2  >10,000 >300 >300 N.S.E. N.S.E. N.T. 
59676 Dpp.Phe.Gly.Leu.Met.NH2  >10,000 partial >300 N.S.E. partial N.S.E. 
59677 pGlu-ln.Phe.Phe.G1y.Leu.Met.Gly.c1y.oMe. >10,000 
agonist 
>300 300 N.S.E. 
agonist 
N.S.E. N.T. 





146.2 >300 5.8 N.T. N.S.E. N.T. 
1,632 >300 >300 N.T. N.S.E. 
62039 Dpp.Gly.Leu.Met.G1y.G1y.0. >10,000 >300 >300 Non N.S.E. N.S.E. 
Competitive 
620140 Dpp.Phe.Gly.Leu.Met.Gly.Gly.0H. >10,000 >300 >300 Non N.S.E. N.S.E. 
Competitive 
620141 pGlu.Gln.Pbe.Phe.Gly.Leu.Leu.Gly.Gly.QMe. >10,000 >300 >300 N.S:E. N.S.E. N.S.E. 
561499 pGlu.Gln.Phe.Phe.Gly.Ile.Met.NH2 3,333 >300 83 N.S.E. N.S.E. N.S.E. 
56500 }-IC1.I-I.Gln.Phe.Phe.Gly.OMe. >10,000 >300 >300 N.S.E. N.S.E. N.S.E. 
56501 pGlu.Gln.Phe.Phe.Gly.OH. >10,000 >300 >300 N.S.E. N.S.E. N.S.E. 
Table 1 
C-terminal Fragments of SP 
3.6.4. Biological Activities 
A list of analogues whose biological activities have been determined is 
given in Tablel. They were tested for in vitro agonist and antagonist activity on 
the guinea pig ileum (GPI), rat colon muscularis mucosae (RC) and rat spinal 
cord (RSC). These tissues are representative of the SP-P, SP-E and neuronal 
tachykinin receptors, respectively. 
The Dpp C-terminal fragments of SP were devoid of any antagonistic 
activity and only Dpp-SP 811(186) showed some agonistic activity on the rat 
colon having a maximal effect which is only 20% of that achieved by SP. This 
activity in a small molecule may reflect differences in the binding requirements 
of the SP-P and SP-E receptors. Interestingly, Dpp-SP 711(189) did not show 
any agonistic activity since SP 7-11  hasIY% activity of SP. This would suggest 
that the Dpp blocking group is preventing binding to the receptor site possibly 
due to an induced unfavourable conformation. If this is so biological testing of 
future analogues must include the deblocked as well as the blocked compound 
to ascertain the total effect of the Dpp group. 
The importance of the C-terminal amide for agonist and antagonist activity 
is reinforced by the lack of activity of the SP extended analogues. The lack of 
activity of (172) and (172) may be due to either the -Gly-GlyOMe functionality 
disrupting the conformation at the active site, or that the tissues contain 
amidating enzymes and (172) and (173) are converted to (190) and (191) 
respectively and the -GIyNH2 functionality causes disruption of the bioactive 
conformation at the active site. A clearer picture of the situation would be 
obtained from the synthesis and biological testing of (190), (191) and (192). The 
reported non-competitive antagonism of (167) and (170) in the GPI has been 
suggested to be because of a non-specific effect on the tissue rather than a 
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selective action at a tachykinin receptor 
The results of these tests have shown that none of the analogues has any 
significant agonistic or antagonistic activity. However, whether any of the 
extended analogues interacted with the amidating enzyme cannot be 





Melting points were taken in an open capillary tube on an electrically 
heated Buchi 510 melting point apparatus and are uncorrected. Optical rotations 
were measured on a AA1000 polarimeter using a 10cm cell. Thin-layer 
chromatography (tic) was carried out on plastic sheets coated with silica gel 
60GF-254 (Merck) in the following systems: (A) CHCI3-MeOH (9:1), (B) 
CHCI3-MeOH (+1% AcOH) (6:1), (C) CHCI3-MeOH (3:2), (D) nBuOH-AcOH-H20 
(3:1:1), (E) nBuOH-AcOH-H2O (4:1:5), (F) EtOAc-Pyr-MeOH-H20 (120:60:3:11). 
Visualisation of the compounds was achieved by a suitable combination of the 
following methods: iodine vapour, uv absorbtion at 254nm, ninhydrin for 
peptides with free amino groups and chlorine starch spray. High performance 
liquid chromatography (hplc) was carried out using a waters HPLC system ie. 
2x6000A pumps, a Waters U6K injector, 680 gradient former, and a Waters uv 
detector (Model 441). Analytical separations were executed on an ODS 5.i 
Hypersil column (3.9x300mm) and semi-preparative separations were carried 
out on an ODS 10 j.i Hypersil column (7.8x300mm) using a gradient over 25 
minutes, as specified in parentheses, between solvent A (0.05% TFA in water) 
and solvent B (0.05% TFA in acetonitrile). The flow rate was lml./miri and 
elution of the samples was monitored at 254 and 229nm. Amino acid analyses 
were carried out on a LKB alpha machine following sealed tube hyrolyses at 
110°C for 18 hours. Theoretical amino acid ratios are shown as a subscript 
following the amino acid in question. Infrared spectra were measured on a 
Perkin Elmer 781 specrophotometer. Ultraviolet spectra were measured in 
distilled methanol on a Pye-Unicam SP8-400 spectrophotometer. High 
resolution and low resolution fast atom bombardment (FAB) spectra were 
Notes 
measured on a Kratos MS50TC machine. Proton nmr spectra were recorded on 
a Bruker WH360 operating at 360MHz or a Bruker WP200 operating at 200MHz. 
Samples were dissolved in deuterated solvents indicated and tetramethylsilane 
(TMS) was used as an internal standard. Carbon-13 nmr spectra were measured 
on a Bruker WP200 machine operating at 50MHz. Samples were dissolved in 
deuterated solvents indicated and all chemical shifts were measured relative to 
TMS assigned at zero. Phosphorus-31 nmr spectra were recorded on a Jeol 
FX-60-Q machine operating at 24MHz.All chemical shifts were measured 
relative to 85% phosphoric acid assigned as zero. All solvents were distilled 
before use and the following were dried from the drying agent in parentheses; 
N,N-Dimethylformamide (DMF) (calcium hydride), ether refers to diethyl ether 
(sodium), dichioromethane (DCM) (calcium hydride). Dpp-amino acids60, amino 
acid methyl esters , as their hydrochloride salt 81  and HBr.Gly-GlyOMe79 were 
prepared following literature methods. 
4.2. Experimental 
N-Diphenylphosphinylphenylalanylmethionine 	methyl 	ester 	(94) 
DppPhe-MetOMe. To a stirred solution of DppPheOH (93) (2.19g. 6mM) in DCM 
(35ml.) cooled to 0°C were added NMM (0.66ml., 6mM) and a solution of 
diphenylphosphinyl chloride (1.42g. 6mM) in DCM (20ml.). After stirring for 
fifteen minutes a solution of HCI.MetOMe (92) (1.00g. 5mM) in DMF (lOmi.) was 
added immediately followed by NMM (0.55m1., 5mM). The resulting mixture was 
stirred at low temperature for one hour before the cooling bath was removed 
and the temperature was allowed to rise to ambient when the reaction solvent 
was removed under reduced pressure to yield a colourless oil containing a 
white solid which was partitioned between ethyl acetate and water. The organic 
phase was washed with saturated NaHCO3 solution (3x5Oml.), water (lxSOml.), 
5% citric acid solution (2x50m1.), water (lxSOml.), saturated NaHCO3 solution 
M. 
Experimental 
(2x50m1.), water (lxSOml.), brine (2x5Oml.) and dried over anhydrous sodium 
sulphate. After filtering off the drying agent the organic solution was 
concentrated under reduced pressure and the desired product (94) was 
crystallised out by the addition of petrol (40-60) (2.1g. 82%),m.p.155-157°C; tic, 
Rf(A)-0.6; (Found: C, 63.1; H, 6.0; N, 5.4. C271-1311\1204PS requires C, 63.5; H, 6.1; N, 
5.5%); [a]22  -69.7' (c 1.0 in MeOH); 'umax (CHBr3 mull) 3360 3260 (N-H), 1740 
(ester C=O), 1665 (amide C=O), 750 699cm 1  (armatic stretching); Xmax  (MeOH) 
207 (25,938), 220 (16,135) (sh), 264 (1,430), 272nm (919); t5 (200MHz, CDCI3) 2.0 
(51-1, m, Met -Cl 2), 2.5 (21-1, tr, Met y-Cl 2), 3.2 (21-1, m, Phe -Cl 2), 3.25 (11-1, m, 
Phe a-CH), 3.75 (4H, m, OCH3 and P-NH), 4.65 (11-1, m, Met ct-CH), 7.15-7.9 (15H, 
m, aromatic H's), 8.19 (11-1, d, Met NH, JNH_aCH7.7HZ); 6c(50MH 	CDCI3) 15.1 
(S-CH3), 29.9 (Met y-C), 31.0 (Met s-C), 39.3 39.5 (d, Phe -C Jp_c6.11-1z), 
51.9(a-C), 52.1 (0-CH3), 56.2 (a-C), 126.7-137.0 (aromatic C's), 171.8 172.0 
(C=O's); Amino acid analysis, Phe1  , Met1  ; hplc, Rt 19.1 mins (20-100%B): 
N-Diphenylphosphinylglycylphenylalanylmethionine methyl ester (98) 
DppGIy-Phe-MetOMe. To a stirred solution of DppPhe-MetOMe (94) (11.2g. 
23mM) in methanol was added a methanolic solution of hydrogen chloride 
(138mM, 6eq.). 31P nmr showed the reaction to be complete after two hours 
whereupon the solvent was removed and the residue was washed with ether 
(3x50m1.) to remove the DppOMe (96) byproduct. The resulting HCI.Phe-MetOMe 
(95) was stored in a dessicator over phosphorus pentoxide until needed. 
DppGlyOH (97) (6.5g, 23mM) was dissolved in DCM (200ml.) and cooled to 
-5°C with stirring. NMM (2.5m1.,23mM) and a solution of DppCl (5.4g,23mM) in 
DCM (10.2m1.) were added dropwise maintaining the low temperature and the 
mixture was stirred for fifteen minutes. HCI.Phe-MetOMe (95) (prepared as 
above) in DMF (lOOmI.), NMM (2.5m1., 23mM) and 2,6-lutidine (2.67ml., 23mM) 
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were added dropwise and the mixture was stirred for one hour below 0°C and 
one hour at ambient temperature. After the removal of the reaction solvent the 
resulting oil was partitioned between ethyl acetate and water and was worked 
up as for (94). The drying agent was filtered from the solution which was 
concentrated and the product was triturated under hexane. Recrystallisation 
from CHCI3 and hexane yielded (98) as a white powder (9.0g. 70%), m.p. 
143-144°C; tic, Rf(A) 0.55; (Found: C, 61.32; H, 6.0; N, 7.4. C29H34N3N5PS requires 
C, 61.4; H, 6.0; N, 7.4%); [a] 2 26.1°; (c 1 in MeOH); max  (CHBr3 mull) 3240 3200 
(N-H), 1750 (ester C=0), 1660 (amide C=O's), 750 695 (aromatic stretches); Xmax 
(MeOH) 203 (51,556), 259 (2,111), 265 (2,389), 272nm (1,778); tSH (200MHz, CDCI3) 
2.0 (51-1, m, S-CH3 and Met B-Cl 2), 2.4 (21-1, tr, Met y-CH2), 3.1 (21-1, d, Phe 
B-Cl 2), 3.55 (21-1, m, Gly ct-Cl 2), 3.6 (31-1, s, OCH3), 4.7 (1H, m, P-NH), 4.6 (11-1, m, 
Met ct-CH), 4.8 (11-1, m, Phe ct-CH), 7.1-7.9 (16h, m, aromatic H's and Met-NH), 
8.7 (11-1, d, Phe-NH); rSC (50MHz,CDCI3) 15.1 (S-CH3), 29.9 (Met y-C), 31.1 (Met 
B-C), 37.6 (Phe l3-C), 44.6 (Gly ct-C), 51.6 (a-C), 52.0 (0-CH3), 54.4 ((x-C), 
126.6-136.6 (aromatic C's), 170.1 170.8 171.8 (C=O's); Sp (24MHz, CDCI3) 25.1; 
m/z 567 492 376 257. HRMS 567.1950 ((M#/-t); Amino acid analysis, Gly1G.09 
,Met10.41) ,Phe1'LO'l ; ; hplc, Rt 21.4 mins. (0-100%B): 
Glycyiphenylalanylmethionine 	methyl 	ester 	hydrochloride. 	(99) 
HCI.GIy-Phe-MetOMe. (98) (11g. 19.4mM) was dissolved in a methanolic 
hydrogen chloride solution (29m1., 116.3mM) and stirred at 35-40°C. 31P nmr 
and tic showed the reaction to be complete within 30 minutes. The solvent was 
removed under reduced pressure and the residue was taken up in a little 
methanol. The desired product (99) was obtained by trituration with anhydrous 
ether as a white powder (6.74g, 86%), m.p. 176-177°C; tic, Rf(E)O.lB; (Found: C, 
49.7; H, 6.5; N, 10.3. C14H28N304SC1 plus 0.5mol of H20 requires C, 49.5; H, 6.6; 
N, 10.2%); [a]22  -8.40 (c 1 in MeOH); umax  (CHBr3 mull) 3500-2500 (NH), 3300 
M. 
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3200 (N-H's), 1740 (ester C=O), 1660 (amide C=O's), 745 695cm 1  (aromatic 
stretches); Xmax  (MeOH) 203nm (17,280); 5H  (200MHz, d6DMSO) 1.95 (2H, m, Met 
g[b]-CH2), 2.05 (3H, s, S-CH3), 2.5 (2H, m, Met y-CH2), 3.9 (2H, m, Phe -CH2), 
3.45 (2H, q, Gly ct-CH2), 3.65 (3H, s, O-CH3), 4.4 (1H, m, Met cz-CH), 4.65 (1H, m, 
Phe ct-CH), 7.25 (5H, m, Phe's aromatic H's), 8.0 (3H, br.s, NH), 8.65 (1H, d, Met 
NH, NH-ctCH78)'  8.7 (1H, d, Phe N-H, JNHCH8•7); 'S (50MHz, d6DMSO) 14.5 
(S-CH3), 29.5 (Met y-C), 30.3 (Met s-C), 37.6 (Phe B-C), 39.9 (Gly ct-C), 51.1 
(a-C), 51.8 (0-CH3), 54.0 (a-C), 126-137 (aromatic C's), 165.5 170.8 171.8 
(C=O's); m/z 369 165. HRMS 369.1722 (EM-Cir); Amino acid analysis, Gly, 1.00, 
Met10.51, Phe1 l.00; 
N-DiphenylphosphinylglycylglycylpheflylalaflYlmethiOflifle methyl ester (100) 
DppGly-Gly-Phe-MetOMe. DppGlyOH (97) (5.2g, 19.25mM) and NMM (2.12ml., 
19.25mM) were dissolved in DMF (20ml.) and in an ice-salt cooling bath to 
-5°C. DppCl (4.55g, 19.25mM) in DCM (14.2m1.) was added dropwise and the 
mixture was stirred for fifteen minutes below 0°C. A chilled solution of (99) 
(6.94g. 17.2mM) in DMF (50m1.), NMM (1.9m1.,17.2mM) and 2,6-lutidine (2.24ml., 
19.25mM) were added dropwise. Stirring was continued for one hour at 0°C and 
one hour at ambient temperature. The reaction mixture was worked up using 
the same procedure as for (94) to yield the product (100) as a white powder 
which would not crystallise from numerous solvent systems. Trace 
contaminants were removed by dry flash silica chromatography using 5% 
MeOH in CHCI3 as the eluant (6.5g, 60%), m.p. 168-169°C; tic, Rf(A)O.S; [c] 2 
-23.50 (c 1 in MeOH); umax  (CHBr3 mull) 3300-3200 (N-H's), 1740 (ester C=O), 
1660 (amide C=O's), 750 700cm 1  (aromatic stretches); Xmax  (MeOH) 208 
(41,980), 259 (1499), 265 (1874), 272nm (1374); 5H  (200MHz, CDCI3) 1.95 (51-1, m, 
Met l3 CH2 and S-CH3), 2.3 (2H, tr, Met i  CH2), 3.05 (2H, m, Phe B CH2), 3.6 (5H, 
m, O-CH3 and G1y1  ct CH2), 3.9 (2H, m, Gly 2 ct CH2), 4.55 (2H, m, Met ct CH and 
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P-NH), 4.8 (11-1, m, Phe c#, C-H), 7.0-7.9 ( 16H, m, Phe NH and aromatic H's), 8.05 
(1H, tr, G1y2 N-H, JNH-ctcH5-2)'  8.1 (11-1, d, Met N-H, JNHCN78); 6c (50MHZ, 
CDCI3) 15.1 (S-CH3), 29.9 (Met y C), 31.0 (Met i3-C), 37.9 (Phe i3-C), 43.1 43.9 
(Gly cs-C's), 51.4 54.4 (Phe and Met c-C's), 52.1 (0-CH3), 126.5-136.7 (aromatic 
C's), 168.7 170.9 171.1 172.0 (C=O's); 6 (24MHz, CDCI3) 27.6; m/z 625 315 258 
201. HRMS 625.2250 ([M+/-t); Amino acid analysis, Gly22.01, Met10.74. Phe1l.00; 
hplc, Rt  20.6mins (0-100%B, 25mins): 
Bis-N,O-Diphenylphosphinyl tyrosine methyl ester (102) DppTyr(Dpp)OMe. A 
solution of DppCl (40.8g. 172.7mM) in DCM (90ml.) and NMM ( 28.5m1.,259mM) 
was added to a suspension of HCI.TyrOMe (20g. 86.3mM) in DCM (75m1.) cooled 
to 0°C. After stirring at low temperature for one hour and at room temperature 
for one hour the solvent was removed under reduced pressure and the residue 
was partitioned between chloroform and water. The organic phase was washed 
with saturated NaHCO3 solution (3x75m1.), water (lx75ml.), 5% citric acid 
solution (2x75m1.), water (1x75m1.), saturated NaHCO3 solution (2x75ml.),water 
(1x75m1.), cold 0.25M NaOH solution (2x75m1.), water (1x75m1.), brine (2x75m1.) 
and dried over anhydrous sodium sulphate. Removal of the drying agent and 
concentration of the solution under reduced pressure precipitated the crude 
product which was recrystallised from chloroform petrol(40-60) mixtures to 
yield pure DppTyr(Dpp)OMe (102) (43.3g, 85%),m.p. 184-186°C (Lit168. 
189-190°C); tic, Rf(A)0.6; []2_2O.3 (c 1 in MeOH); vm,, (CHBr3 mull) 3380 (N-H), 
1740 (ester C=O), 750 695cm (aromatic stretches); Xmax  (MeOH) 207 (49,812), 
223 (45,481), 260 (3,898), 267 (4,548), 274nm (3,465); SH (200MHz, CDCI3) 2.95 
(2H, d, B-CH2, ctCH-CH 6.11-1z), 3.55 (41-1, m, O-CH3 and ct-CH), 3.95 (1H, m, 
P-NH), 7.05 (4H, ABq, Tyr aromatic H's), 7.2-7.9 (24H, m, Dpp aromatic H's); tSc 
(50MHz, CDCI3) 40.38 40.46 (d, B-C, Jp_c4.11-1z), 51.9 (0-CH3), 54.6 (a-C), 
120.6-133.4 (aromatic C's), 149.9 150.1 (d, Tyr C4, jp_c8.2Hz), 172.8 173.0 (CO3 
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Jp_c5.7H 	, (24MHz, CDCI3) 23.3 (P-NH), 30.6 (P-O); hplc, Rt 23 mins 
(0-100%B): 
N-Diphenylphosphinyl tyrosine dicyclohexylamine salt (103) DppTvrOH.DCHA. 
DppTyr(Dpp)OMe (102) (5.96g, 10mM) was dissolved in peroxide free 
1,4-dioxane (70m1.) and 1M sodium hydroxide solution (25ml.) was added. The 
resulting clear, pale yellow solution was stirred for at room temperature for 
five hours when tic showed the reaction to be complete. The dioxane was 
removed under reduced pressure and the resulting aqueous solution was 
acidified to pH 3 with saturated citric acid precipitating out of solution a white 
gum. This gum was extracted into ethyl acetate (3x30m1.), the organic solution 
was washed with water (2x2Oml.), brine (2x2Oml.) and dried over anhydrous 
sodium sulphate. After removing the drying agent the solvent was evaporated 
off under reduced pressure to leave a white foam which was dissolved in ethyl 
acetate (lOmI.) and dicyclohexylamine (2.5ml., 12mM) was added causing white 
crystals to deposit immediately. These were filtered and recrystallised from 
methanol ether mixtures to yield DppTyrOH.DCHA (103) (4.22g, 75%), 
m.p.218-220°C (Lit. 218-2200C); (Found: C, 70.4; H, 7.7; N, 4.9. C33H43N204P 
requires C, 70.4; H, 7.7; N, 5.0%); [] 2 +142o (c 1 in MeOH); 'umax  (CHBr3 mull) 
3500-2800 (-NH), 3160 (N-H), 2940 2860 (aliphatic C-H's), 1570 (CO), 745 
695cm 1  (aromatic stretches); cS (200MHz, d6DMSO) 1.0-2.0 (21-1, m, DCHA 
CH2's), 2.65-3.00 (41-1, m, -CH2 and DCHA CH's), 3.4 (11-1, m, ct-CH), 4.8 (11-1, m, 
P-NH), 6.8 (41-1, q, Tyr aromatic H's), 7.3-7.8 (10H, m, Dpp aromatic H's), 9.2 (11-1, 
br.s, phenolic -OH); 6C (50MHz, d6DMSO) 24.2 25.2 (DCHA C's), 30.5 (8-C), 52.1 
(0-CH3), 56.0 (a-C), 114.4-135.4 (aromatic C's), 155.5 (Tyr C4), 164.1 (C=O); 6 
(24MHz, d6DMSO) 25.0; 
N-Diphenvlphosphinyl 	tyrosine 	dihydrate 	(105) 	DppTyrOH.H20 
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DppTyrOH.DCHA (103) (2.63g, 4.67mM) was suspended in ethyl acetate and an 
equal volume of citric acid was added and the mixture was shakened until all 
the solid had dissolved. The organic solution was then washed with saturated 
citric acid (2x2Oml.) and water (3x20m1.) before drying over anhydrous sodium 
sulphate. After removing the drying agent the solution was concentrated to half 
volume under reduced pressure and hexane was added dropwise until the 
solution became cloudy whereupon it was cooled to yield DppTyrOH.2H20 as a 
white crystaline solid (1.75g. 90%), m.p. 85-86°C; tIc, Rf(0)0.2; (Found: C, 60.1; H, 
5.8; N, 3.4; C21H24N06P (includes 2 moles of H20) requires C, 60.4, H, 5.8, N, 
3.4%); E]2_1510 (c 1 in MeOH); 'umax (CHBr3 mull) 3600-2200 (-0O2H), 3260 
(N-H), 1745 (acid C=O), 750 700cm 1  (aromatic stretches); Xmax  (MeOH) 204 
(23,003), 225 (24,116), 265 (2,597), 273nm (2,579); SH (200MHz, d6DMSO) 2.8 (21-1, 
m, -Cl 2), 3.75 (11-1, m, ct-CH), 3.9 (11-1, m, P-NH), 6.7 (41-1, q, Tyr aromatic H's), 
7.05-7.70 (10H, m, Dpp aromatic H's); Sc (50MHz, d6DMSO) 38.9 39.0 (d, l3-C, 
Jp_c6.3H), 55.4 (a-C), 115.1-133.7 (aromatic C's), 156.2 (Tyr C4), 174.0 (C=O); 
m/z381.1130 (Ill); hplc, Rt  17.6 mins (0-100%B, 25mins): 
Diphenyiphosphinyl phenyl ester (112) DppOPh To a stirred solution of 
phenol (0.94g, 10mM) and NMM (1.1ml., 10mM) in DCM (lOml.) cooled to -5°C 
was added a solution of DppCl (2.36g. 10mM) in DCM (lOmi.) dropwise so as to 
maintain the low temperature. Stirring was continued below 0°C for one hour 
and at ambient temperature for one hour after which the solvent was removed 
under reduced pressure and the residue was worked up as for (102). After 
removing the drying agent the solution was concentrated under reduced 
pressure and hexane was added dropwise until the resulting cloudiness 
persisted. Cooling resulted in the desired product crystallising out as white 
needle shaped crystals. These were filtered and dried over phosphorus 
pentoxide m.p. 137-138°C; tIc, R[f(A)10.60; vmax  (CHBr3 mull) 3380 3360 
Experimental 
(aromatic C-H's), 1590 (aromatic C=C), 1440 (P-Ph), 770 750 730 700cm 1  
(aromatic stretches); Xmax  (MeOH) 208 (20,110), 223 (15,406), 264 (1,646), 272nm 
(1,176); SH (80MHz, CDCI3) 6.9-8.2 (m, aromatic H's); 6 (24MHZ, CDCI3) 30.4; 
N_DiphenylphosphinityrosyIglycylglycyIpheflylalaflYlmethiOflifle methyl ester 
(108) DppTyr-Gly-Gly-Phe-MetOMe. DppGiy-Gly-Phe-MetOMe (100) (6.4g, 
10.25mM) was dissolved in a methanolic hydrogen chloride solution and stirred 
at 35-40°C. 31P nmr and tic showed the reaction to be complete after half an 
hour whereupon the solvent was removed under reduced pressure and the 
residue was washed with dry ether several times. DppTyrOH.2H20 (105) (4.7g, 
11.28mM) was dissolved in DMF (30m1.) and left over 4A molecular sieves for 
three hours. The solution was decanted and cooled to -5°C in an ice salt bath 
and NMM (1.24ml., 11.28mM) and DppCl (2.67g, 11.28mM) in DCM (5ml.) were 
added dropwise. Stirring was continued for fifteen minutes when a chilled 
solution of HCI.Gly-Giy-Phe-MetOMe (prepared as above) in DMF (30m1.) was 
added followed by NMM (1.13ml., 10.25mM) and 2,6-lutidine (1.31m1., 10.28mM). 
After stirring for one hour at 0°C and one hour at room temperature the 
reaction solvent was removed under reduced pressure and the residue was 
worked up as for (94). The dried organic solution was concentrated under 
reduced pressure and cooled to -20°C to yield the desired product as a white 
powder (4.9g. 61%), m.p. 116-118°C; tic, Rf(A)O.S; (Found: C, 61.0; H, 5.9; N, 8.9. 
C40H46N508PS plus 1.5mol of water requires C, 60.0; H,6.1; N,8.6%); (cd2_60.50 
(c 1 in MeOH); 'umax (CHBr3 mull) 3300 (br, N-H), 1740 (ester C=O), 1655 (amide 
C=O), 750 695cm 1  (aromatic stretches); Xmax  (MeOH) 213 (23,493), 225 (21,010), 
266 (2,101), 273nm (2,149); 6H (360MHz, CDCI3) 1.9 (21-1, m, Met -CI-12), 2.0 (31-1, 
s, Met S-CI 3), 2.3 (21-1, m, Met y-CH2), 2.95 (21-1, m, Tyr -Cl 2), 3.1 (21-1, m, Phe 
B-Cl 2), 3.6-3.9 (81-1, m, Gly's ct-CH2's, Tyr ct-CH and O-CI 3), 4.35 (11-1, m, Met 
c-CH), 4.65 (11-1, m, Phe c-CH), 4.9 (11-1, m, P-NH), 6.8 (41-1, ABq, Tyr aromatic 
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H's), 7-7.75 (13H, m, NH's and aromatic H's), 8.45 (11-1, br.s, Gly N-H); 6 (50MHz, 
CDCI3) 15.1 (S-CH3), 29.7 (Met y-C), 31.0 (Met s-C), 37.8 (Phe s-C), 39.0 (Tyr 
B-C), 43.1 43.7 (Gly ct-C's), 51.6 (a-C), 52.1 (OCH3), 54.6 (ce-C), 57.0 (Tyr CL-C), 
115.6-136.8 (aromatic C's), 155.9 (Tyr C4), 169.5 170.1 171.3 171.8 174.4 (C=O's); 
6 (24MHz, CDCI3) 21.4; m/z (FAB) 788 (0), 478, 421, 336 and 201. HRMS 
788.2883 ([Mi-I-I'); Amino acid analysis, Gly22.15, Met1O.48, Tyr10.95, Phe10.98; 
hplc, R  17.2 mins (20-100%B): 
N-DiphenyltyrosylglycylglycylphenylaianylmethiOflifle (115) 
DppTyr-Gly-Glv-Phe-MetOH. (108) (2g. 2.54mM) was dissolved in DMF (lOmi.) 
and 1M NaOH solution (5.3m1., 5.3mM) was added with stirring. Stirring 
continued for six hours when tic showed the saponification to be complete. 
The solvent was removed under reduced pressure at room temperature and the 
residue was taken up in some water (5m1.) and acidified to pH 3 with saturated 
citric acid solution. The resulting white gum was extracted with ethyl acetate 
(3x15ml.) washed with water (2xlOml.), brine (2xlOml.) and dried over anhydrous 
sodium sulphate. was obtained by trituration with petrol (40-60), After removal 
of the drying agent the solution was concentrated and the product (115) (1.78g, 
91%), tIc Rf(B)0.5; [ct] 2 -54.0 (c 1 in MeOH); 'Umax (CHBr3 mull) 3650-2700 
(COOH), 3300 (N-H), 1725 (acid C=O), 1660 (amide C=O), 750 700cm 1  (aromatic 
stretches); Xma, (MeOH) 211 (22,751), 225 (17,799), 267 (1,857), 274nm (2,012); 
'H (360MHz, d6DMSO) 1,9 (21-1, m, Met -Cl 2), 2.0 (31-1, s, S-CH3), 2.45 (21-1, m, 
Met y-CH2), 2.8 (21-1, m, Tyr -Cl 2), 2.95 (2H, m, Phe -Cl 2), 3.45 (11-1, m, Tyr 
ct-CH), 3.6-3.85 (41-1, m, Gly c-CH2's), 4.2 (11-1, m, Met 	-CH), 4.55 (11-1, m, Phe 
c-CH), 5.9 (11-1, m, P-NH), 6.9 ( 4H, q, Tyr aromatic H's), 7.1-7.7 (10H, m, Dpp 
aromatic H's), 7.9 (11-1, d, Phe N-H, JNH_CHB.SHZ), 8.3 (11-1, d, Met N-H, 
jNH(tcH7'7)' 8.6 (11-1, tr, Gly N-H, JNH_aCHS.SHZ), 8.7 (11-1, tr, Gly N-H, 
JNH_cLcH5.9HZ); 6c (50MHz, d6DMSO) 14.7 (S-CH3), 29.8 (Met y-C), 30.8 (Met 
W. 
Experimental 
B-C), 37.7 (Phe B-C), 38.4 (Tyr B-C), 420. 42.8 (Gly (L-C), 51.3 ((x-C), 53.8 (a-C), 
57.3 (a-C), 57.3 (Tyr ct-C), 115-137 (aromatic C's), 156.2 (Tyr C4), 168.7 169.5 
171.3 173.1 173.7 (C=O's); m/z775 , 478, 421, 336, 201. HRMS 774.2726 ([M#/-t); 
Amino acid analysis, Tyr10.92, G1y22.04, Phe1l.06, Met1l.00; hplc, Rt 19.0 mins 
(0-100%B, 25mins): 
Tyrosylglycylglycylphenylalanylmethionine (116) Tyr-Gly-Gly-Phe-Met. (1 15) 
(774mg, 1mM) was dissolved in a 2M solution of hydrogen chloride in a 2:1 
mixture of water and peroxide free dioxane (6m1., 12eq.). 3 P nmr showed the 
deprotection to be complete after six hours. The solution was lyophilised and 
the solid was redissolved in a minimum of 5% aqueous acetic acid and applied 
to a Sephadex G15 gel filtration column eluted with 5% acetic acid to yield 
361mg (63%) of product with a minor impurity. This was easily removed either 
by reverse phase semi-preparative hplc or by partition chromatography on 
Sephadex G25 using a nBuOH:AcOH:H20 (4:1:5) solvent system (220mg, 26%), 
m.pi%°C; tic, Rf(E)  0.43; (Found: C, 55.4; H, 6.2; N, 11.8. C27H35N507S plus 0.5mol 
of acetic acid requires C, 55.7; H, 6.2, N, 11.6 %); [ct] 2-20.8° (c 0.5, H20); 'umax 
(CHBr3 mull) 3600-2500 (NH), 3300 (N-H), 1750-1630 (br,C=O); Xmax  (MeOH) 196 
(42,452); 3H (360MHz, d6DMSO) 1.9 (2H, m, Met B-CH2), 2.05 (3H, s, Met S-CH3), 
2.50 (2H, m, Met y-CH2 ), 2.85 (2H, m, Tyr B-CH2), 2.95 (2H, m, Phe B-CH2), 
3.6-3.9 (4H, m, Gly ct-CH2's), 4.0 (1H, br.s, Tyr ct-CH), 4.35 (1H, m, Met ct-CH), 
4.6 (1H, m, Phe ct-CH), 6.9 (4H, ABq, Tyr aromatic H's), 7.2 (5H, m, Phe aromatic 
H's), 8.1 (5H, br.s, d, tr, NH, Phe N-H and Gly N-H), 8.38 (1H, d, Met N-H, 
jNH_ CH78), 8.77 (1H, tr, Gly N-H, JN_cLCH5.6HZ); m/z 574, 185. HRMS 
574.2335 ([M+/-t); Amino acid analysis, Tyr10,95, Gly22.01, Phe1l.05, Met1l.01; 
hplc, Rt  21.4 mins (0-60%B): 
N-Diphenylphosphinyl methionyl glycyl glycine methyl ester (160) 
Experimental 
DppMet-Gly-GiyOMe. DppMetOH (158) (lOg, 0.029mM) was dissolved in DCM 
(250ml.) and cooled to -5°C whereupon NMM (3.19ml., 0.029mM) and DppCl 
(6.8g, 0.029mM) in DCM (24.2ml.) was added dropwise so as to maintain the low 
temperature. After fifteen minutes of stirring HBr.Gly-GlyOMe (159) (6.0g. 
0.026mM) in DMF (40ml.) was added dropwise followed by NMM (2.9ml., 0.026M) 
and the reaction mixture was stirred below 0°C for one hour and allowed to 
rise to ambient temperature before removing the solvent and working up the 
residue as for (94). The product was obtained slightly impure and was further 
purified by dry flash silica chromatography using 5% MeOH in CHCI3 as the 
eluant to yield DppMet-Gly-GlyOMe (160) as a white foam (11.2g, 93%), tic, 
Rf(A) 0.4; Vmax  (CHBr3 mull) 3440 3260 (N-H), 1740 (ester C=O), 1670 (amide 
C=O); Xmax  (MeOH) 203 (18,719), 224 (11,365), 264 (1,242), 271m (955); 5H 
(200MHz, CDCI3) 1.95 (51-1, m, S-CH3 and Met -Cl 2), 2.45 (21-1, m, Met y-CH2), 
3.6 (41-1, m, O-CH3 and Met ct-CH), 3.85 (41-1, m, Glys' ct-Cl 2's), 4.65 (11-1, m, 
P-NH), 7.25-7.85 (10H, m, aromatic H's), 7.9 (11-11, tr, Gly N-H), 8.65 (11-1 , tr, Gly 
N-H); SC (50MHz, CDCI3) 14.8 (S-CH3), 29.9 (Met y-C), 33.0 (Met s-C), 40.7 42.5 
(Glys' ct-C's), 54.1 (Met ct-C), 128.3-132.7 (aromatic C's), 169.8 170.0 173.0 
(C=O's); 6F'  (24MHz, CDCI3) 25.1; m/z 478 304 256 201. HRMS 478.1565 ([M+/-t); 
Amino acid analysis, Met13.40,  G1y2 200; hplc, Rt 18.3 mins (0-100%B): 
Methionyiglycyiglycyl methyl ester hydrochloride (161) HCI.Met-Gly-GIyOMe 
DppMet-Gly-GlyOMe (160) (lOg, 21mM) was dissolved in a minimum of 
methanol and a methanolic solution of hydrogen chloride (40ml., 126mM) was 
added with stirring. The reaction mixture was warmed to 35-40°C in a water 
bath and the progress was monitored by 31P nmr and tic which showed it to 
be complete after 20 minutes. The solvent was removed and the residue was 
triturated with ether to give a white powder. This was recrystallised from 
methanol ether mixtures to yield HCI.Met-Gly-GlyOMe (161) (5.6g, 85%), m.p. 
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109-111°C; tic, Rf(d)0.36; [ct]22 +230  (c 1 in MeOH); umax (CHBr3 mull) 3600-2400 
(NH), 3340 3205 (N-H), 1745 (ester C=O), 1655 (amide C=O's), 750 700cm 1  
(aromatic stretches); Xmax  (MeOH) 205 (15,314); 6H  (200MHz, d6DMSO) 2.05 (51-1, 
m, S-CH3 and Met B-Cl 2), 2.55 (21-1, m, Met y-Cl 2), 3.65 (31-1, s, O-CI 3), 3.9 (51-1, 
m, Glys' ct-CH2 and Met ct-CH), 8.5 (31-1, br.s, NH), 8.6 (11-1, tr, Gly N-H), 9.0 (11-1, 
tr, Gly N-H); cS t (50MHz, d6DMSO) 14.4 (S-CH3), 28.3 (Met y-C), 30.8 (Met s-C), 
40.9 41.8 (Glys' ct-C's), 51.7 (0-CH3 and Met ct-C), 168.5 168.8 170.1 (C=O's); 
m/z 279 ([M-CA, 100%), 218, 190, 148. HRMS 278.1174 (EM-Ct); Amino acid 
analysis, G1y22.00, Met10.34; hplc, Rt 4.2 mins (20-100%B): 
N-DiphenylphosphinylleucylmethionylglyCylglYCifle methyl ester (163) Dpp 
Leu-Met-Gly-GlyOMe. DppLeuOH (162) (6.0g. 18mM) was dissolved in dry 
dichloromethane (200m1.) and cooled to -5°C with stirring. NMM (1.98m1., 
18mM) and a solution of DppCl (4.26g, 18mM) in dichloromethane (32m1.) was 
added dropwise so as to maintain the low temperature. Stirring was continued 
for 15 minutes afterwhich HCI.Met-Gly-GlyOMe (161) (5.0g. 16) dissolved in 
DMF (35ml.) was added dropwise followed by NMM (1.76ml., 16mM) . The 
reaction mixture was stirred for one hour at -5°C and one hour at ambient 
temperature. The solvent was removed and the residue was worked up 
following the same procedure as for (94) yielding the desired product slightly 
impure. The trace impurities were removed by dry flash silica chromatography 
using 5% MeOH in CHCI3  as the eluant to give DppLeu-Met-Gly-GlyOMe (163) 
as a white powder. Attempted recrystallisations yielded only a gelatinous 
precipitate (7.5g, 70%), m.p.191-192°C; tic, Rf(A)0.47;  (Found: C, 57.0; H, 6.8; N, 
9.5. C281-1391\1406PS requires C, 56.9; H, 6.7, N, 9.5%); 
[(X]22  -60.40  (c 1 	in MeOH); 
max (CHBr3 mull) 3280 3240 (N-H), 1750 (ester C=O), 1670 1640 (amide C=O's), 
750 695cm 1  (aromatic stretches); Xmax (EtOH) 260 (1,100), 268 (1,416), 271m 
(1,130); 	6H  (360MHz, CDCI3) 0.84 (61-1, q, Leu 	6-CH3's), 	1.7 (2H, m, Leu -CH2), 
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1.8 (11-1, m, Leu y-CH2), 2.05 (31-1, s, Met S-CH3), 2.3 (21-1, m, Met B-Cl 2), 2.55 
(21-1, m, Met y-CH2), 3.5 (11-1, m, Leu ct-CH), 3.55 (31-1, s, O-CI 3), 3.75 (21-1, m, Gly 
ct-CH2), 4.2 (21-1, m, Gly ct-Cl 2), 4.25 (11-1, m, Met ct-CH), 4.5 (1H, m, P-NH), 
7.3-7.75 (12H, m, aromatic H's and 2NH's), 9.1 (11-1, tr, Gly NH); 6 	(20MHz, 
CDC13) 15.0 (S-CH3), 21.8 22.6 (Leu 6-C's), 24.5 (Leu rny-C), 29.9 (Met y-C), 30.4 
(Met B-C), 40.6 43.0 (Glys' ct-C's), 43.3 43.7 (d, Leu B-C, Jp_c8.8Hz), 51.8 
(0-CH3), 53.3 53.9 (a-C's), 127.3-134.7 (aromatic C's), 169.9 171.5 174.5 (C=O's); 
(24MHZ, CDCI3) 24.4; m/z 591.5468 ([M#/i1); Amino acid analysis, G1y22.02, 
Met10.55, Leu10.99; hplc, A  16.7 mins (20-100%B): 
N-Diphenylphosphinylleucylmethionylglycylgiycine (164) 
DppLeu-Met-Gly-GIyOH. (163) (500mg, 0.85mM) was suspended in dioxane 
(5m1.) at room temperature and a 1M NaOH solution (0.85ml., 0.85mM) was 
added. After three minutes a clear solution was formed and after seven hours 
the reaction was finished as seen on tic. The dioxane was removed under 
reduced pressure and the resulting aqueous solution was acidified to pH 3 with 
saturated citric acid solution. A white gum precipitated out and was extracted 
into ethyl acetate (3x2Oml.). The organic solution was washed with water 
(2x20m1.), brine (2x20m1.) and dried over anhydrous sodium sulphate. After 
filtering off the drying agent the solution was concentrated and cooled to yield 
DppLeu-Met-Gly-GlyOH (164) as a white floculant powder. The product was 
filtered and dried (409mg, 85%), m.p. 189°C; tic, Rf(Z)0.23;  (Found: C, 54.7; H, 6.5; 
N, 9.3. C271-1391\1407PS (includes one mol of H20) requires C, 54.5; H, 6.6; N, 
9.4%); [a]12  61.1' (c 1 in MeOH); 'umax  (CHBr3 mull) 3500-2600 (CO2H), 3340 
3260 (NH's), 1780 (acid C=O), 1660 (amide C=O's), 750 700cm 1  (aromatic 
stretches); Xmax  (MeOH) 203 (34,138), 222 (15,801), 261 (1,615), 271m (1,153); 
(360MHz, d6DMSO) 0.77 (61-1, q, Leu S-CI 3), 1.5 (21-1, m, Leu B-Cl 2), 2.0 (31-1, 
m, Leu y-CH and Met B-Cl 2), 2.0 (31-1, s, S-CI 3), 2.3 (21-1, m, Met y-CH2), 3.3 
72 
Experimental 
(1H, m, Leu ct-CH obscured by the water signal), 3.7 (21-1, d, Gly ct-Cl 2), 3.79 
(2H, dq, Gly ct-CH2), 4.3 (11-1, m, Met ct-CH), 5.6 (lh, m, P-NH), 7.5-7.85 (10H, m, 
aromatic H's), 8.0 (11-1, tr, Gly NH, JNH_ctCH5.SHZ), 8.14 (11-1, d, Met NH, NH-ctCH 
7.7Hz), 8.75 (1H, tr, Gly NH,4SJHCHS.SHz); 	(50MHz, d6DMSO) 14.6 (S-CH3), 
21.6 22.9 (Leu 6-C's), 23.9 (Leu y-C), 29.6 (Met y-C), 31.3 (Met B-C), 40.6 42.0 
Glys' ct-C's), 43.1 (Leu l3-C), 51.8 53.6 ((x-C's), 128.4-133.5 (aromatic C's), 169.1 
171.0 171.4 173.7 (C=O's); 6, (24MHz, d6DMSO) 22.1; m/z 557 286 201. HRMS 
577.2250 ([M#M); Amino acid analysis, Gly21.95, Met10.85, Leu1l.03; hplc, R 
15.2 mins (20-100%B): 
N-DiphenylphosphinylglycylleuCylmethiOflylglVCylglYCifle methyl ester (166) 
DppGIy-Leu-Met-GIy-GlyOMe. To a stirred solution of (163) (500mg, 0.85mM) 
in methanol (2m1.) was added a solution of hydrogen chloride in methanol 
(45mL, 5.1mM). Stirring was continued until tIc and 31P nmr showed the 
reaction to be complete two hours later. The solvent was removed under 
reduced pressure and the residue was washed with dry ether several times and 
stored in a dessicator over phosphorus pentoxide until needed. DppGlyOH 
(465mg, 1.69mM) was stirred in DMF (5ml.) and cooled to -5°C when NMM 
(0.186m1., 1.69mM) and a solution of DppCl (400mg, 1.69mM) in DCM (1.92ml.) 
were added dropwise. The mixture was stirred <0°C for fifteen minutes and 
then a solution of HCI.Leu-Met-Gly-GlyOMe (722mg, 1.69mM) in DMF (2m1.) 
NMM (0.186 ml.,1.69mM) and 2,6-lutidine (0.196m1., 1.69mM) were added. 
Stirring was continued for one hour at 0°C and one hour at room temperature. 
The solvent was removed under reduced pressure and the residue taken up in 
a minimum of fresh DMF and applied to a gel filtration column (2.5x8Ocm) 
packed with Sephadex LH20 and eluted with DMF. The product was obtained 
(650mg, 60%) slightly impure and was further purified by wet flash silica 
chromatography using 5% MeOH in CHCI3 as the eluant to yield 
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DppGly-Leu-Met-Gly-GlyOMe as a white powder (596mg, 55%), m.p. 
216-217°C; tic, Rf(A)0.29;  (Found: C, 55.2; H, 6.6; N, 10.6. C301-1421\1507PS requires 
C, 55.6; H, 6.5; N,10.8%); 
[a]22  -28.7 (c 1 in MeOH); 'max  (CHBr3 mull) 3280 3240 
(NH's), 1750 (ester C=O), 1680 1660 1610 (amide C=O's), 750 730 700cm 1  
(aromatic stretches); Xmax  (MeOH) 207 (24,873), 225 (14,509), 267 (1,160), 274 
(777); 6 (200MHz, d6DMSO) 0.85 (61-1, dd, Leu 6-CH3'S), 1.55 (31-1, M, LEU B-CH2 
AND r-CH), 2.0 (51-1, m, S-CH3 and Metl3-CI-12), 2.5 (21-1, m, Met y-Cl 2), 3.4 (21-1, 
m, Gly ct-CH2), 3.75 3.85 (41-1, d's, GIyctCH2's), 4.4 (21-1, m, Leu and Met ct-CH's), 
5.8 (11-1, m, P-NH), 7.4-7.9 (10H, m, aromatic H's), 8.1-8.5 (41-1, m, NH's); 6 
(50MHz, d6DMSO) 14.7 (S-CH3), 21.6 23.2 (Leu 6-C's), 24.2 (Leu rny-C's), 29.7 (Met 
y-C), 31.5 (Met s-C), 40.4 40.7 41.7 (Glys' ct-C's), 43.4 (Leu s-C), 51.1 52.2 
(a-C's), 51.6 (0-CH3), 128.7-134.0 (aromatic C's), 169.3 170.2 171.5 172.3 
(C=O's); 6, (24MHz, d6DMSO) 23.5; Amino acid analysis, G1y33.00, Met10.54, 
Leu1l.00; hpic, R{t} 20.1 mins (20-100%B): 
N_Diphenylphosphinylgiycylleucylmethionylglycylglycifle (167) 
DppGly-Leu-Met-GIy-GIyOH. To a stirred suspension of (166) (100mg, 
0.154mM) in peroxide free dioxane (2mi.) was added 1M NaOH solution 
(0.16m1.,0.16 mM). The mixture was stirred for thirty minutes when tic showed 
the reaction to be complete. The dioxane was removed under reduced pressure 
and the aqueous mixture was acidified to pH 3 with saturated citric acid. The 
water was removed and the residue redissolved in a minimum of DMF and 
applied a gel filtration column (lx50cm) packed with Sephadex LH20 and eluted 
with DMF. Fractions 25-28 were pooled and the solvent removed under reduced 
pressure to leave a residue which when triturated with ether yielded the 
desired product as a white powder (60mg, 61%), m.p. 171-172°C; tic, Rf(Z)0.19; 
[ct] 2-30.00 (c 1 in DMF); Vmax  (CHBr3 mull) 3280 (NH), 1740 (ester C=O), 1640 
(amide C0), 750 695cm 1  (aromatic stretches); Xmax  (MeOH) 205 (30,798), 221 
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(20,095), 266 (1,458), 277nm (1,204); 6H (360MHz, d6DMSO) 0.85 (6H, q, Leu 
6-CH3's), 1.5 (31-1, m, Leu -CH2 and y-CH), 1.9 (2h, m, Metl3-CI-12), 1.95 (31-1, s, 
S-CI 3), 2.5 (21-1, m, Met y-CH2), 3.3 (2h, m, G1y1  ct-CH2 obscured by the water 
signal), 3.8 (41-1, m, G1y45 ct-Cl 2's), 4.5 (21-1, m, Leu and Met ct-CH's), 5.7 (1H, m, 
P-NH), 7.4-7.9 (10H, m, aromatic H's), 8.1 (51-1, m, Gly NH's and Leu or Met NH), 
8.3 (11-1, d, Leu or Met NH, JNH_aCH7.8HZ); m/z 634 258 230 201. HRMS 634.2464 
([Mi-I-i); Amino acid analysis, G1y32.96, Met10.96, Leu1l.01; hplc, Rt 23.5mins 
(0-1 00%B): 
N_DiphenylphosphinylphenylalanylglycylleuCylmethiOflVlglvCYlglvCifle methyl 
ester (169) DppPhe-Gly--Leu-Met-Gly-GlyOMe. (166) (735mg, 1.13mM) was 
dissolved in a minimum of methanol and a solution of hydrogen chloride in 
methanol (3.4m1., 6.8mM) was added and the mixture was warmed to 35-40°C 
with stirring. 31Pnmr and tic showed the reaction to be complete after 30 
minutes. The solvent was removed under reduced pressure and the residue 
was washed with ether several times and stored in a dessicator until needed. 
DppPheOH (170) (413mg, 1.13) was dissolved in dichloromethane (5m1.) and 
cooled to -5°C whereupon NMM (124p1., 1.13mM) and a solution of DppCl 
(267mg,1.13mM) in dichioromethane (0.45m1.) was added dropwise. Stirring was 
continued for fifteen minutes and then a solution of HCI.Gly-Leu-
Met-Gly-GlyOMe (168) (1.13mM) in DMF (5ml.) was added dropwise followed by 
NMM 124il., 1.13mM) and 2,6-lutidine (131 j.il., 1.13mM). The reaction mixture 
was stirred for one hour at 0°C and one hour at room temperature after which 
the solvent was removed under reduced pressure and the residue was worked 
up in the same manner as for (94). Concentration of the dried organic solution 
and cooling led to the crystallisation of the desired product which was then 
filtered and dried (652mg, 68%), m.p. 172-174°C; tic, Rf(A)0.45;  (Found: C, 58.9; 
H, 6.5; N, 10.5. C391-151N60813S requires C, 58.8; H, 6.5; N, 10.2%); [c] 2-46.9° (c 1 
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in MeOH); 'max (CHBr3) 3320 (NH), 1750 (ester C=O), 1660 (amide C=O's), 750 
695cm 1  (aromatic stretches); Xmax  (MeOH) 206 (21,622), 227 (9,539), 268 
(1,272), 274nm (954); iS (360MHz, d6DMSO) 0.82 (61-1, q, Leu 6-CH3's), 1.7 (31-1, 
m, Leu y-CH and -Cl 2), 2.0 (31-1, s, S-CI 3), 2.05 (21-1, m, Met -Cl 2), 2.3 (21-1, 
m, Met y-Cl 2), 2.9 (21-1, m, Phe -Cl 2), 3.5 (11-1, m, Phe ct-CH), 3.6 (31-1, s, 
O-CH3), 3.65-3.9 (61-1, m, Gly ct-Cl 2's), 4.4 (2H, m, Leu and Met ct-CH's), 6.0 (11-1, 
m, P-NH), 7.1-7.7 (15H, m, aromatic H's), 7.96 (11-1, d, Leu or Met NH, 
NH-ctCH7'9' 8.1 (11-1, tr, Gly NH, JNH_ctCKS.8HZ), 8.3 (1H, tr, Gly NH, NH-ctCH5•9' 
8.7 (11-1, d, Leu or Met NH, JNH_ctCH8.SHZ), 8.6 (1H, tr, Gly NH, JNH_ CHS.9Hz); 
(60mg, 61%), cS t (50MHz, d6DMSO) 14.6 (S-CH3), 21.4 22.9 (Leu 6-C's), 29.5 (Met 
y-C), 31.7 (Met B-C), 38.5 38.7 (Phe l3-C, J_c1O4H, 40.3 40.4 41.7 (Gly ct-C's), 
42.5 (Leu s-C), 51.6 51.8 (a-C's), 51.9 (0-CH3), 56.9 (a-C), 126.4-138.1 (aromatic 
C's), 169.0 169.2 170.0 171.2 172.3 173.6 (C=O's); iS (24MHz, d6DMSO) 21.5; 
Amino acid analysis, Phe1l.01 , Gly 3.10 , Leu1096, Met10.66 ; hplc, R 
19.4mins (20-100%B): 
N_DiphenylphosphinylphenylalanylglyCylleuCyimethiOflYlglvCviglvCifle (170) 
DppPhe-GIy-Leu-Met-Giy-GIyOH. To a stirred suspension of (169) (250mg, 
0.32mM) in peroxide free dioxane (2m1.) was added 1M NaOH solution (0.35m1., 
0.35mM). Stirring was continued for 4 hours when tic showed the reaction to 
be complete. The dioxane was removed under reduced pressure and the 
residue was worked up in the same manner used for (163) to yield 
DppPhe-Gly-Leu-Met-Gly-GIyOH (170) as a white powder (166mg, 68%), 
m.p.225-227°C; tic, Rf(8)0.22; [ct] 2 -31.9° (c 1 in MeOH); 'umax (CHBr3 mull) 
3600-2800 (CO21-1), 3340 3280 (NH), 1740 (acid C=O), 1640 (amide C=O's), 750 
690cm 1  (aromatic stretches); Xmax  (MeOH) 209 (59,348), 270 (10,620), 276nm 
(9,995); 6H  (360MHz, d6DMSO) 0.8 (6H, dd, Leu 6-CH3's), 1.5-1.9 3H, m, Leu 
-CH2 and y-CH), 1.95 (31-1, s, S-CI 3), 2.0 (21-1, m, Metl3-CI-12), 2.45 (2H, m, Met 
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y-CH2), 2.95 (21-1, d, Phe B-Cl 2), 3.5 (11-1, m, Phe c-CH), 3.6-3.9 (61-1, m, Gly 
ct-Cl 2's), 4.4 (21-1, m, Leu and Met ct-Cl 2's), 6.1 (11-1, m, P-NH), 7.1-7.3 (15H, m, 
aromatic H's), 8.0 (11-1, d, Leu or Met NH, JNH_CNS.OHZ), 8.05 (11-1, tr, Gly NH, 
JNH_CHS.9HZ), 8.15 (11-1, tr, Gly NH, JNH_CHS.8HZ), 8.6 (11-1, d, Leu or Met NH, 
JNH_CH8.4HZ), 8.7 (11-1, tr, Gly NH, JNH_CH,S.7HZ); m/z 803 320 201. HRMS 
781.3148 ([M+h1); Amino acid analysis, Phe1 l.OL, , Gly3 2,E32, Leu1l.03 , Met1101 
hplc, Rt 18.1 mins (20-100%B): 
N-Diphenylphosphinylleucylglycylglycine 	methyl 	ester 	(174) 
DppLeu-Gly-GlyOMe. To a stirred solution of DppLeuOH (2.3g. 6.9mM) in dry 
dichloromethane (20ml.) at -5°C was added NMM (0.76m1.,6.9mM) and a solution 
a DppCl (1.63g. 6.9mM) in dichloromethane (3.5m1.) dropwise .Stirring was 
continued for fifteen minutes after which a solution of HBr.Gly-GlyOMe (1.4g. 
6.3mM) in DMF (lOmI.), NMM (0.69ml., 6.3mM) and 2,6-lutidine (0.79ml., 6.9mM) 
were added dropwise. The reaction mixture was stirred for one hour below 0°C 
and one hour at ambient temperature. The solvent was removed under reduced 
pressure and the residue was worked up following the same procedure as for 
(94). DppLeu-Gly-GlyOMe was obtained as an off white foam which was 
slightly impure as seen on tic. The trace impurities were removed by wet flash 
silica chromatography using 5% MeOH in CHCI3 as the eluant to yield the 
product (174) as a white foam (2.5g. 85%), tic, Rf(A)0.36; umax (CHBr3 mull) 3260 
(NH's), 1750 (ester C=O), 1660 (amide C=O's), 750 695cm 1  (aromatic stretches); 
Xmax  (MeOH) 205 (22,607), 225 (14,520), 267 (1,678), 276nm (1,011); 6H  (200MHz, 
CDCI3) 0.75 (61-1, q, Leu 6-CH3's), 1.55 (2H, dd, Leu -CH2), 1.7 (11-1, m, Leu 
y-CH), 3.45 (11-1, m, Leu cL-CH), 3.55 ( 3H, s, O-CI 3), 3.9 (41-1, m, Gly c-Cl 2's), 4.3 
(11-1, m, P-NH), 7.3-7.9 (11H, m, aromatic H's and Gly NH), 8.95 (11-1, tr, Gly NH); 
6c (50MHz, CDCI3) 21.8 22.7 (Leu 6-C's), 24.4 (Leu 1-C), 40.9 42.8 (Gly a-C's), 
43.3 43.5 (d, Leu 8-C, 4_c 92H, 51.8 (0-CH3), 53.8 (Leu ct-C), 128.3-133.2 
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(aromatic C's), 170.1 170.2 174.0 (C=O's); S (24MHz, CDCI3) 24.7; m/z 460.2001 
([M#h1); hplc, Rt 15.7 mins (20-100%B): 
Leucyl glycylglycine methyl ester hydrochloride (175) HCLLeu-Gly-GlyOMe. 
A solution of (174) (1.1g. 2.4mM) and hydrogen chloride (14.4mM) in methanol 
was stirred at 40°C for thirty minutes when the reaction was shown to be 
complete by tic and 31 P nmr. The solvent was removed under reduced 
pressure yielding a white solid which was washed with ether and recrystallised 
from methanol ether mixtures. The product was filtered off and dried to yield 
hygroscopic white crystals (454mg, 64%), m.p. 99-101°C; tic Rf(D)0.61; Xmax 
(MeOH) 204 (5,235); 6H  (200MHz, d6DMSO) 0.9 (61-1, dd, Leu 6-CH3's), 1.7 (31-1, m, 
Leu 	-CH2 and y-CH), 3.4 (11-1, br.s, Leu a-CH), 3.6 (31-1, s, O-CI 3), 3.8 (41-1, m, 
Gly ct-Cl 2's), 8.45 (31-1, br.s, NH), 8.6 (1H, tr, Gly NH, JNH_CRS.8HZ), 9.05 (1H, tr, 
Gly NH, JNH_(XcHS.6Hz);  6c  (50MHz, d6DMSO) 21.9 22.0 (Leu 6-C's), 23.2 (Leu 
y-C), 39.9 (Leu s-C), 40.4 41.8 (Gly ce-C's), 50.7 (Leu ct-C), 51.2 (0-CH3), 168.3 
168.9 169.6 (C=O's); m/z260.1610 (EM-Cu 1 ); hplc, Rt 3.Omins (20-100%B): 
N-Diphenylphosphinylleucylleucylglycylglycine 	methyl 	ester 	(176) 
DppLeu-Leu-Gly-GlyOMe. To a stirred solution of DppLeuOH (739mg, 2.2mM) 
in dry dichioromethane (25ml.) at -5°C was added NMM (0.25ml., 2.2mM) and a 
solution of DppCl (520mg, 2.2mM) in dry dichloromethane (0.6m1.) dropwise so 
as to maintain the low temperature. After stirring for fifteen minutes 
HCI.Leu-Gly-GlyOMe (175) (600mg, 2.0mM), NMM (0.22ml.,2.OmM) and 
2,6-lutidine (0.26m1.,22mM) were added dropwise and stirring was continued for 
one hour below 0°C and one hour at ambient temperature. The solvent was 
removed under reduced pressure and the residue was worked up in th same 
manner as for (94) to yield crude (178). The product was further purified either 
by gel filtration on Sephadex LH20 with MeOH as the eluant or by wet flash 
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silica chromatography using 5% MeOH in CHCI3 as the eluant. (176) was 
obtained as a white powder which refused to crystallise in various solvent 
systems (871mg, 76%), m.p. 187-188°C; tic, Rf(A)0.40;  (Found: C, 60.5; H, 7.3; N, 
9.6; P, 5.5. C291-1411\1406P requires C, 60.8; H, 7.2; N, 9.8; P. 5.4%); vm,x (CHBr3 
mull) 3280 (NH), 1745 (ester C=O), 1680 1660 (amide C=O's), 700 730cm 1  
(aromatic stretches); Xmax (EtOH) 222 (15,866), 264 (1,291), 271m (922); 6 
(200MHz, CDCI3) 0.85 (12H, m, Leu 6-CH3's), 1.7 (61-1, m, Leu B-Cl2's and 
y-CH's), 3.55 (41-1, s, m, O-CH3 and Leu ct-CH), 3.9 (41-1, m, Gly ct-CH2's), 4.2 (21-1, 
m, P-NH and Leu ct-CH), 7.1-7.95 (12H, m, aromatic h's, Gly NH and Leu NH), 
8.95 (1H, tr, NH); cS (20MHz, CDCI3) 21.4 21.9 22.8 23.1 (Leu 6-C's), 24.7 25.0 
(Leu y-C's), 39.5 40.7 (Glyct-C's), 43.2 43.7 (Leu i3-C's), 51.9 (0-CH3), 53.2 54.3 
(Leu ct-C's); SF (24MHz, CDCI3) 24.5; Amino acid analysis, Gly22.02, Leu21.98; 
hplc, Rt  17.6 mins (20-100%B): 
pyro-GlutamlglutamylphenylalanylpheflylaIaflylgIYCYlleUCYlmethiOflVl9IYCYl9l 
ycine methyl ester (172) pGIn-Gin-Phe-Phe-Gly-Leu-Met-GlyGlyOMe. 
Method A: HCI.Leu-Met-Gly-GlyOMe (165) was prepared by stirring (164) 
(112mg, 0.2mM) for one hour with a methanolic solution of hydrogen chloride 
(0.6ml., 1.2mM). The reaction was followed by 31P nmr and tic. The solvent was 
removed under reduced pressure and the resulting brown oil was washed with 
ether and dried under vacuum over phosphorus pentoxide. 
pGln-Gin-Phe-Phe-GIyOH (171) (122mg, 0.2mM) was stirred in DMF (2m1.) and 
cooled to -25°C. NMM (2241., 0.2mM) and CptCl (27.7mg, 0.2mM) in DCM (8041) 
was added dropwise so as to maintain the low temperature. The solution was 
stirred for fifteen minutes after which a solution of (165) (0.2mM) in DMF (4m1.) 
to which NEM (25]l., 0.2mM) had been added immediately before, was added. 
Stirring was continued for one hour below -20°C and one hour at room 
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temperature. The solvent was removed under reduced pressure and the residual 
oil was taken up in a minimum of DMF and applied to a chromatography 
column packed with Sephadex LH20 and eluted with DMF. The product was 
obtained slightly impure and applied to a second gel filtration column (1x50cm) 
eluted with DMF from which it was obtained in a pure form (43mg, 22%). 
Method B. The title compound was prepared in the same manner as 
described in method A except that the reaction was allowed to stir at room 
temperature for five hours. The work up procedure was identical to yield (172) 
as a white powder (100mg, 51%). 
Method C. (165) (0.2mM) was prepared as described in method A and stored 
in a dessicator over phosphorus pentoxide until needed. (200) (122mg, 0.2mM) 
and N-hydroxybenzotriazole (27.5mg, 0.4mM) were dissolved in DMF (4m1.) and 
cooled to 0°C. A solution of DCCI (80mg, 0.4mM) in DMF (lml.) was added 
dropwise to the stirred solution. Ten minutes later a solution of (166) (0.2mM) 
in DMF (2m1.) and NMM (22l. 0.2mM) was added and stirring was continued for 
2 hours at 0°C and 22 hours at ambient temperature. The reaction mixture was 
worked up following the same procedure used in method A to yield the (172) 
(256mg, 67%), SH  (360MHz, d6DMSO) 0.85 (6H, dd, Leu 6-CH3's), 1.5 (21-1, dd, Leu 
-CH2), 1.65 1.80 (41-1, m, Gini3-CI-12), 1.8 (11-1, m, Leu y-CH), 1.95 (1H, m, Met 
-Cl 2), 2.0 (3H, s, S-CI 3), 2.1 (41-1, m, Gin y-CH2), 2.45 (21-1, m, Met y-CH2), 2.8 
2.95 (41-1, m, Phe 6-CH2's), 3.6 (3H, s, O-CI 3), 3.7 (41-1, m, Gly ct-CH2's), 3.85 (2H, 
d, Gly cL-CH2), 4.05 (1H, m, pGln ct-CH), 4.2 (11-1, m, Gin ct-CH), 4.3 (21-1, m, Leu 
and Met ct-CH' s), 4.5 (21-1, m, Phe c-CH's), 6.75 (11-1, br.s, Gin iry amide NH), 
7.1-7.25 (10H, m, aromatic H's), 7.8 (11-1, s, pGln NH), 8.05 (11-1, d, Leu NH), 8.1-8.4 
(71-1, m, NH's); m/z 981.4504 ([M-th1); Amino acid analysis, G1n22.03, Gly32.95, 




Method A. (176) (94mg, 0.16mM) was dissolved in methanol (imi.) and a 
solution of hydrogen chloride in methanol (0.30ml., 1.0mM) was added. After 
stirring for two hours at room temperature 31  P nmr and tIc showed the 
reaction to be complete. The solvent was removed and the the residue was 
washed with ether several times and stored in a dessicator over phosphorus 
pentoxide until needed. (173) (100mg, 0.16mM) was dissolved in DMF (lOml.) 
and cooled to -20°C. NEM (18j.il., 0.16mM) and CptCl (23mg, 0.16mM) in DCM 
(92l.)were added dropwise maintaining the low temperature. Stirring was 
continued for fifteen minutes when a solution of (177) (0.16mM) in DMF (lml.) 
was added dropwise. This was followed by NEM (21l., 0.16mM) and stirring 
was continued for one hour below 0°C and for one hour at room temperature. 
The reaction mixture was worked up in the manner as for (172) to yield (173) 
as a white powder (41mg, 26%). 
Method B. (173) was prepared following the same procedure as outlined in 
method A except that 2,6-lutidine (19l., 0.16mM) was added after adding the 
final aliquot of NEM (53mg, 34%). 
Method C. (177) (0.16mM) was prepared following the same procedure 
outlined in method A and stored in a dessicator over phosphorus pentoxide 
until needed. (173) (100mg, 0.16mM) and N-hydroxybenzotriazole (22mg, 
0.32mM) were dissolved in DMF (4m1.) and cooled to 0°C. A solution of DCCI 
(64mg, 0.32mM) in DMF (imI.) was added dropwise and the reaction mixture 
was stirred for ten minutes. A solution of (177) (0.16mM) in DMF (2m1.) and 
NMM (18i.il., 0.16mM) were added to the mixture and stirring was continued for 
2 hours at 0°C and 22 hours at room temperature. The reaction mixture was 
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worked up following the same procedure as for (172) to yield (173) as a white 
powder (107mg, 68%), 6H (360MHz, d6DMSO) 0.85 (12H, m, Leu 6-CH3's), 1.45 
(41-1, m, Leu B-Cl2's), 1.65 1.80 (41-1, m, Gin 	-CH2'0, 2.1 (41-1, m, Gin y-CH2's), 
2.85 2.95 (41-1, m, Phe 	-CH2's), 3.65 (31-1, s, O-CI 3), 3.7 (41-1, m, Gly ct-CH2's), 
3.85 (21-1, m, Gly cL-Cl 2), 4.0 (11-1, m, pGln ct-CH), 4.2 (11-1, m, Gin ct-CH), 4.25 4.35 
(21-1, m, Leu ci-CH's), 4.5 4.55 (21-1, m, Phe a-CH's), 6.8 (11-1, br.s, Gin iry amide 
NH), 7.1-7.25 (10H, m, aromatic H's), 7.75 (11-1, s, pGln NH), 7.92 (11-1, d, Leu NH, 
JNH.CHS.2HZ), 7.97 ( 1H, d, Phe NH, JNH_cH8.2Hz), 8.01 (11-1, d, Gin NH, 
JNH_CH8.SHZ), 8.04 (11-1, d, Leu NH, JNH_CH8.4HZ), 8.11 (11-1, tr, Gly NH), 8.2 (31-1, 
m, Phe NH and 2xGly NH's); m/z 964 217. HRMS 963.4940 ([M#/-1); Amino acid 
analysis, G1n22.13, G1y32.91, Leu21.91, Phe22.06; hplc, R  15.2mins (20-100%B): 
N-DiphenylphosphinylleucylmethiOflifle methyl ester (178) DppLeu-MetOMe. 
To a stirred solution of DppLeuOH (lOg, 30.2mM) in dry DCM (50ml.) cooled to 
-5°C was added NMM (3.3m1., 30.2mM) and a solution of DppCl (7.1g. 30.2mM) 
in dry DCM (35.5m1.) dropwise so as to maintain the low temperature. Stirring 
was continued for fifteen minutes when a solution of HCI.MetOMe (5.5g, 
27.5mM) in DMF (20m1.) was added followed by NMM (3.0ml., 27.5mM) . The 
reaction mixture was stirred for one hour at -5°C and one hour at room 
temperature. The solvent was removed and the residual oil was worked up in 
the same manner as for (94). The desired product was obtained slightly impure 
and so was recrystallised from ethyl acetate petrol (40-60) mixtures (10.5g, 
80%), m.p. 165-167°C; tIc, Rf(A)  0.64; (Found: C, 60.2; H, 5.8; N, 6.9. 
C241-1331\1204PS requires C, 60.5; H, 5.9; N, 7.0%); [(1122 -49.80 (c 1 in MeOH); umax 
(CHBr3) 3360 3250 (NH), 1740 (ester C=O), 1665 (amide C=O's), 750 695nm 
(aromatic stretches); Xmax  (MeOH) 205 (39,270), 220 (20,970), 265 (1,525), 273nm 
(1,144); 5H  (200MHz, CDCI3) 0.80 (61-1, dd, Ley 6-CH3's), 1.5 (11-1, m, Leu y-CH), 
1.75 (21-1, m, Leu -CH2), 2.05 (51-1, m, S-CH3 and Met -CH2), 2.5 (21-1, dd, Met 
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y-CH2), 3.6 (21-1, m, P-NH and Leu ct-CH), 3.75 (31-1, s, O-CH3), 4.6 (11-1, m, Met 
ct-CH), 7.3-7.9 (10H, m, aromatic H's); 6 (50MHZ, CDCI3) 15.2 (S-CH3), 21.9 22.6 
(Leu 6-C's), 24.4 (Leu 1-C), 30.0 31.2 (Met 	and y-C's), 43.5 43.7 (d, Leu s-C, 
4c5.7H, 51.7 53.1 (ct-C's), 52.1 (0-CH3), 128.3-133.3 (aromatic C's), 172.0 
173.2 (C=O's); 6 (24MHz, CDCI3) 24.8; Amino acid analysis, Leu1l.00, Met1O.51; 
hplc, Rt  17.8 mins (0-100%B): 
N-DiphenylphosphinylglycylleuCylmethiOflifle (180) DppGly-Leu--MetOMe. 
(174) (877mg, 1.84mM) was dissolved in a minimum of methanol and a 
methanolic solution of hydrogen chloride (4.8ml., 11mM) was added. The 
solution was stirred for thirty minutes at 35-40°C when 
31 P nmr and tIc 
showed the reaction to be complete. The solvent was removed under reduced 
pressure and the residue was washed with ether several times and dried in a 
vacuum over phosphorus pentoxide. DppGlyOH (506mg, 1.84mM) was dissolved 
in dry dichloromethane and cooled to -5°C . NMM (0.2ml., 1.84mM) and a 
solution of DppCl (435mg, 1.84mM) in dry DCM (5.3ml.) were added dropwise 
and the reaction mixture was left to stir for fifteen minutes. A solution of 
HCI.Leu-MetOMe (179) (1.84mM) in DMF (2ml.) and NMM (0.20m1.1.84mM) were 
then added and the reaction was left for a further one hour at -5°C and one 
hour at room temperature. The solvent was removed and the residual oil was 
worked up as for (94). The resulting crude product was initially purified by gel 
filtration on Sephadex LH20 with MeOH as the eluant followed by droplet 
counter current chromatography using nBuOH:AcOH:H20 (4:1:5) solvent system 
but poor yields of only 23% (270mg) were obtained. A repeat experiment 
purified the product on a dry flash column over silica eluting with 5% MeOH in 
CHCI3 to the product pure in final yield of 51% (501mg), m.p. 156°C; tIc, 
Rf(A)0.60; (Found C,58.1; H, 6.7; N, 7.9. C26H35N305PS requires C, 58.5; H, 6.8; N, 
7.9%); [0t]22 -35.10 (c 1 in MeOH); umax  (CHBr3  mull) 3350 3230 (NH), 1740 (ester 
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C=O), 1660 (amide C=O's), 750 695cm 1  (aromatic stretches); Xmax  (MeOH) 204 
(20,065), 224 (14,088), 264 (3,415), 272nm (2,988); 6H  (360MHz, CDC13) 0.9 (61-1, 
dd, Leu 6-CH3's), 1.7 (31-1, m, Leu 	-CI-12  and y-CH), 2.05 (51-1, m, S-CH3 and 
Meth-CI-12), 2.5 (21-1, dd, Met ''CH2), 3.4 (51-1, m, O-CH3 and Giy ct-Cl 2), 3.95 (11-1 
q, P-NH), 4.55 (11-1, m, Met a-CH), 4.65 (11-11, m, Leu ct-CH), 7.35 (lh, d, Leu NH, 
JNH__CH7.9HZ), 7.45-7.9 (1 OH, m, aromatic H's), 8.0 (11-1, d, Met NH, 
NH-ccH8' 	
(50MHz, CDC13)  15.3 (S-CH3), 21.9 22.8 (Leu 6-C's), 24.9 (Leu 
y-C), 30.1 31.6 (Met 	and y-C's), 128.6-132.5 (aromatic C's), 170.4 171.9 172.1 
(C=O's); 6 (24MHz, CDC13) 27.2; m/z 534 343 258 201. HRMS 534.2191 ([M#I-4); 
Amino acid analysis, Gly10.95 , Leu1l.02 , Met10.57; hplc, Rt 16.8 mins 
(0-100%B): 
N-DiphenylphosphinylglycyiieucylmethiOflifle (183) DppGiy-Leu-MetOH. 
(180) (1g. 1.84mM) was suspended in peroxide free dioxane (20m1.) and stirred 
while 2M NaOH solution (1.03m1., 2.06mM) was added. Stirring was continued at 
room temperature for four hours after which tic showed the saponification to 
be complete . The dioxane was removed under reduced pressure and the 
resulting oil was worked up in the same manner as for (163). The resulting 
crude product was recrystallised from CHC13 hexane mixtures to yield 
DppGly-Leu-MetOH (183) (826mg, 85%), m.p. 163-163.5°C; ticRf(B)0.26; (Found: 
C, 57.5; H, 6.6; N, 8.0. C25H34N305PS requires C,57.8; H, 6.6; N, 8.1%); [ct]2_24.30 
(c 1 in MeOH); umax  (CHBr3 mull) 3600-2400 (CO21-1), 3380 3320 3195 (NH's), 
1740 (acid C=O), 1660 (amide C=O's), 750 700cm 1  (aromatic stretches); Xmax 
(MeOH) 205 (20,784), 224 (14,272), 260 (970), 266 (1,109), 274nm (831); tSH 
(200MHz, CDC13)  0.9 (61-1, dd, Leu 6-1-I's), 1.5 (31-11, m, Leu -CI-12  and y-CH), 2.0 
(51-1, m, Met -CH2 and S-CI 3), 2.5 (21-1, m, Met y-CH2), 3.4 (21-1, m, Gly ct-Cl 2), 
4.35 (21-11, m, Leu and Met ct-CH), 5.8 (11-1, m, P-NH), 7.4-7.95 (10H, m, aromatic 
H's), 8.05 8.45 (21-1, d's, Leu and Mey NH's); 6c  (50MHz, CDC13) 14.5 (S-CH3), 21.7 
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22.9 (Leu 6-C's), 24.0 (Leu rny-C), 29.8 30.7 (Met B and y-C's), 41.4 (Gly ct-C), 
43.4 (Leu s-C), 50.9 51.1 ((x-C's), 128.3-134.1 (aromatic C's), 169.6 171.9 172.8 
(C'O's); 6 (24MHz, CDCI3) 28.2; m/z 520 320 258 219 (100%). HRMS 520.2035 
([MM); Amino acid analysis, Leu1l.00, Met10.87, G1y11.00; hplc, Rt 18.4 mins 
(0-100%B): 
N-Diphenytphosphinylglycylleucylmethionine 	 amide 	 (182) 
DppGly-Leu-MetNH2. (180) (lg, 1.87mM) was dissolved in a saturated solution 
of ammonia in methanol (5m1.) and stirred overnight when tic showed the 
reaction to be complete. The solvent and excess ammonia were removed under 
reduced pressure and the resulting oil was triturated with petrol (40-60). The 
precipitated crude product was filtered and recrystallised from CHCI3 hexane 
mixtures to give DppGly-Leu-MetNH2 (688mg, 71%), m.p. 90-92°C; tic, Rf(A)0.35; 
[ct] 2 -31.30 (c 1 in MeOH); Vmax  (CHBr3 mull) 3280 (NH), 1690 1650 1630 (amide 
C=O's), 750 700 cm-1  (aromatic stretches); Xmax  (MeOH) 204 (24,479), 224 
(15,351), 264 (1,660), 272nm (1,245); SH  (200MHz, CDCI3) 0.9 (6H, dd, 6-CH3's), 
1.6 (3H, m, Leu -CH2 and y-CH), 2.0 (5H, m, S-CH3 and Met -CH2), 2.5 (2H, 
m, Met y-CH2), 3.65 (2H, m, Gly (t-CH2), 4.5 (3H, m, P-NH, Met and Leu (I-CH's), 
5.85 (1H, br.s, iry amide NH), 7.3 (lh, br.s, iry amide NH), 7.35-7.85 (10H, m, 
aromatic H's), 7.9 8.1 (2H, d's, NH's); 6c  (50MHz, CDCI3) 15.2 (SCH3), 21.7 22.9 
(Leu 6-C's), 24.9 (Leu y-C), 30.4 30.9 (Met 	and y-C's), 41.1 (Gly (X-C), 44.6 
(Leu -C9, 52.4 53.1 (ct-C's), 128.6-132.3 (aromatic C's), 171.2 172.5 173.9 
(C=O's); m/z 519 371 343 258 230 201. HRMS 519.2195 ([M+hfl; Amino acid 
analysis, G1y11.01, Leu10.99, Met10.93; hplc, Rt 13.4 mins (25-100%B): 
N-Dipheny;phosphinylphenylalanylglycylleucylmethiOnifle methyl ester (184) 
DppPhe-GIy-Leu-MetOMe. (180) (4.8g. 4.97mM) was dissolved in a minimum of 
methanol and a methanolic solution of hydrogen chloride (8.83m1., 20.3mM) was 
Experimental 
added with stirring. The temperature was raised to 35-40°C and the reaction 
was stirred for thirty minutes after which it was shown to be complete by 31P 
nmr and tic. The solvent was removed and the residue was washed with ether 
several times and dried in a vacuum over phosphorus pentoxide. DppPheOH 
(2g, 5.47mM) was dissolved in dry DCM (lOmi.) and cooled to -5°C with stirring. 
NMM (0.6ml., 5.47mM) and a solution of DppCl (1.29g, 5.47mM) were added 
dropwise and the reaction was left for fifteen minutes whereupon a solution of 
HCI.Gly-Leu-MetOMe (183) (4.97mM) in DMF (5m1.) and NMM (0.55m1., 4.97mM) 
were added. Stirring was continued for one hour at -5°C and one hour at 
ambient temperature. The solvent was removed under reduced pressure and 
the residual oil was worked up in the same fashion as for (94). The dried ethyl 
acetate solution was concentrated and the product was obtained by trituration 
with petrol (40-60) (2.4g, 71%), m.p. 205°C; tic, Rf(A)0.52; (Found: C, 61.8; H, 6.6; 
N, 8.1. C351-1451\1406PS requires C, 61.8; H, 6.7; N, 8.3%); [a] 2 -62.40 (c 0.5 in 
MeOH); 'max  (CHBr3 mull) 3300 (NH), 1740 (ester C=O), 1660 (amide C=O's), 750 
695cm 1  (aromatic stretches); Xmax  (MeOH) 205 (28,866), 224 (15,522), 265 
(2,179), 273nm (1,906); 6H (360MHz, CDCI3) 0.9 (61-1, dd, Leu 5-CH3's), 1.75 (31-1, 
m, Leu -CI-12  and y-CH), 1.95 (51-1, m, S-CH3 an Met-CH2), 2.5 (21-1, dd, Met 
y-CH2), 3.1 (21-1, m, Phel3-CI-12), 3.7 (41-1, m, O-CH3 and Phe ct-CH), 3.8 (11-1, m, 
P-NH), 4.0 (21-1, m, Gly ct-Cl 2), 4.55 (1H, m, Leu aCH), 4.6 (11-1, m, Met ct-CH), 
7.1-7.7 (17H, m, aromatic H's and NH 's), 8.2 (1H, d, Leu NH, JNH_ C .,B.SHz); 
Amino acid analysis, Phe1l.01 , Gly0.97, Leu1l.02 , Met10,55 ; hplc, Rt 20.5 
mins (25-100%B): 
N-DiphenylphosphinylphenylalanylglycylleucylmethiOflifle (185) 
DppPhe-GIy-Leu-MetOH. (184) (ig, 1.47mM) was suspended in peroxide free 
dioxane (lOmi.) and 1M NaOH solution (1.6m1., 1.6mM) was added with stirring. 
Tic showed the reaction to be complete after four hours. The solvent was 
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removed under reduced pressure and the residue was worked up in the same 
manner as for (164) to yield (187) after recrystallisation from ethyl acetate 
(754mg, 77%), m.p. 189-191°C; tic, Rf()0.73, Rf()0.24; [ct] 2 -52.3° (c 1 in MeOH); 
umax (CHBr3 mull) 3280 (NH), 1730 (acid C=O), 1650 (amide C=O's), 750 700cm 1  
(aromatic stretches); SH  (200MHz, d6DMSO) 0.9 (61-1, dd, Leu 5-CH3's), 1.65 (3H, 
m, Leu -CH2 and i-CH), 2.0 (5h, m, S-CH3 and Met -CH2), 2.45 (21-1, dd, Met 
i-CH2), 2.95 ( 2H, m, Phe -CI-12), 3.5 (11-1, m, Phe ct-CH), 3.8 (21-1, m, Gly ct-CH2), 
4.4 (21-1, m, Leu and Met ctCH's), 6.0 (11-1, m, P-NH), 7.1-7.5 (15H, m, aromatic 
H's), 8.05 (11-1, d, Leu or Met NH), 8.5 (1H, d, Leu or Met NH), 8.6 (11-1, tr, Gly NH); 
6 (50MHz, d6DMSO) 14.6 (S-CH3), 21.5 23.0 (Leu 6-C's), 24.1 (Leu y-C), 29.7 
30.9 (Met B and y-C's), 38.7 (d, Phe B-C, JlO.8Hz), 40.6 (Gly ct-C), 42.5 (Leu 
B-C), 51.0 51.4 56.9 ((x-C's), 126.4-138.4 (aromatic C's), 168.7 172.1 172.9 173.4 
(C=O's); S (24MHz, d6DMSO) 21.7; m/z 667 201. HRMS 667.2719 ([M#I-i1); 
Amino acid analysis, Phe10.95 , G1y1  1.00 , Leu1l.05 , Met10.94; hplc, Rt 22.4 
mins (0-100%B): 
N-Diphenylphosphinylphenylalanylglycylleucylmethionine 	amide 	(186) 
DppPhe-Gly-Leu-MetNH2. (184) (681mg, 1mM) was dissolved in a saturated 
solution of methanol in ammonia (5m1.) and stirred overnight. Tic showed the 
reaction to be complete and so the solvent and excess ammonia were removed 
under reduced pressure and the product was triturated outof solution. 
Recrystallisation from CHCI3 hexane mixtures gave (188) as a white powder 
(473mg, 70%), m.p. 98-100°C; tic, Rf(A)0.33; [(1]22 -55.60 (c 0.5 in MeOH); Vmax 
(CHBr3) 3300 (NH), 1660 (amide C=O's), 750 730 700 (aromatic stretches); Xmax 
(MeOH) 208 (34,470), 227 (16,260), 268 (1,463), 273nm (976); tSH (360MHz, 
d6DMSO) 0.85 (61-1, dd, Leu 5-CH3), 1.7 (3H, m, Leu -CH2 and y-CH),1.9 (31-1, s, 
S-CI 3), 1.95 (21-1, m, Metl3-CI-12), 2.4 (21-1, m, Met y-CH2), 2.9 (21-1, m, Phe 
-Cl 2), 3.25 (31-1, s, O-CI 3), 3.5 (11-1, m, Phe (t-CH), 3.8 (21-1, m, Gly ct-Cl 2), 4.25 
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(11-1, m, Met ct-CH), 4.35 (11-1, m, Leu ct-CH), 6.0 (11-1, m, P-NH), 7.1-7.35 (17H, m, 
aromatic H's and iry amide NH's), 7.7 (11-1, d, Met NH, JNH_CHB.3HZ), 8.56 (11-1, d, 
Leu NH, JNH_CH8.2HZ), 8.6 (1H, tr, Gly NH, JNH_CHS.9HZ);  6, (24MHz, d6DMSO) 
21.5; m/z 666 405 320 201 (100%). HRMS 666.2879 ([M#/-,T'); Amino acid 
analysis, Phe1l,03 , Gly10.93, Leu1l.04 , Met10.94 ; hplc, Rt  22.2 mins 
(0-100%B): 
N_DiphenylphosphinylphenylalaflylpheflylalaflylglvCVlleUCVlmethiOflifle (188) 
DppPhe-Phe-Gly-Leu-MetOMe. (184) (ig, 1.47mM) was dissolved in a minimum 
of methanol and warmed to 35-40°C when a solution of hydrogen chloride in 
methanol (4.2ml., 8.81mM) was added. The reaction was shown to be complete 
after thirty minutes by tic and 31P nmr. The solvent was removed under 
reduced pressure and the residue was triturated with dry ether yielding a white 
hygroscopic powder which was washed with more dry ether and dried over 
phosphorus pentoxide until needed. To a stirred solution of DppPheOH (592mg, 
1.62mM) in DCM (5m1.) cooled to -5°C was added NMM (0.16m1., 1.62mM) and a 
solution of DppCl (383mg, 1.62mM) in dry DCM (1.9m1.) dropwise. The reaction 
was stirred for fifteen minutes after which a solution of 
HCI.Phe-Gly-Leu-MetOMe (187) (1.47mM) in DMF (5m1.) was added followed by 
NMM (0.15m1., 1.47mM). Stirring was continued for one hour at -5°C and one 
hour at room temperature. The solvent was removed and the residue was 
worked up using the same procedure as for (94) to yield 
DppPhe-Phe-Gly-Leu--MetOMe (188) after recrystallisation from ethyl acetate 
(584mg. 48%), m.p. 239-240°C; tic, Rf(A)0.56; [a122-1 08.0' (c 0.5 in MeOH); umax 
(CHBr3  mull) 3300 3210 (NH), 1740 (ester C=O), 1660 1630 (amide C=O's), 750 
695cm 1  (aromatic stretches); Xma. (MeOH) 212 (55,310), 261 (3,974), 267 
(4,637), 274nm (3,974); 6H (360MHz, CDCI3) 0.85 (61-1, m, Leu 6-CH3's), 1.5 (31-1, m, 
Leu 	-CI-12  and y-CH), 2.0 (21-1, m, Met -CI-12), 2.05 (31-1, s, S-CI 3), 2.45 (21-1, m, 
Experimental 
Met B-Cl 2), 3.0 (21-1, m, Phe 	-Cl 2), 3.2 (21-1, m, Phe B-Cl 2), 3.5 (11-1, m, Phe1  
a-CH), 3.7 (4H, m, O-CH3  and P-NH), 4.0 (21-1, m, Gly ct-Cl 2), 4.2 (11-1, m, Phe2 
ct-CH), 4.4 (2H, m, Leu and Met (t-CH's), 6.9 (11-1, d, Leu or Met NH), 7.0-7.5 (17H, 
m, aromatic H's and NH's); m/z 828 552 320 (100%) 201. HRMS 828.3560 
([M#M); Amino acid analysis, Phe21.95 , Gly1t0 , Leu1t02 , Met10,56; hpic, 
Rt  25.4 mins (0-100%B): 
N_DiphenylphosphinylphenylalaflylpheflvlalaflVlglVCvlleUCVlmethiOflifle amide 
(189) DppPhe-Phe-Gly-Leu-MetNH2. (188) (66mg, 0.08mM) was dissolved in a 
saturated solution of ammonia in methanol (Sml.) and stirred for three days 
afterwhich the reaction was shown to be complete by tic. The solvent and 
excess ammonia were removed under reduced pressure and the product was 
triturated with hexane. The resulting off white powder was filtered and applied 
to a wet flash chromatography column eluted with 8% MeOH in CHCI3 to yield 
the desired compound (41mg, 63%), umax (CHBr3 mull) 3300 (NH), 1650 (amide 
C=O's), 750 695cm 1  (aromatic stretches); Xmax  (MeOH) 204 (33,495), 224 
(13,333), 262 (1,138), 268 (1,303), 276nm (813); 6H  (360MHz, d6DMSO) 0.8 (61-1, 
dd, Leu 6-CH3's), 1.3 (11-1, m, Leu y-CH), 1.8 (21-1, m, Leu 	-CI-12), 2.05 (31-1, s, 
S-CI 3), 2.2 (21-1, m, Met -Cl 2), 2.6 (21-1, m, Met y-CH2), 2.9 (21-1, m, Phe -Cl 2), 
3.2 (2H, m, Phe -CH2), 3.5 (2H, m, Phe -CH2), 3.8 (1H, m, P-NH), 3.9 (2H, m, 
Gly ct-CH2), 4.25 (11-1, m, Phe ct-CH), 4.45 (21-1, m, Leu and Met ct-H's), 5.25 5.7 
(21-1, br. s's. NH2), 7.0-7.3 (23H, m, aromatic and NH's), 9.45 (11-1, tr, Gly NH); m/z 
813 552 320 201. HRMS 813.3563 ([M+h1); Amino acid analysis, Phe22.1') , Gly10.97 
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